Page last updated: 2024-11-12

novobiocin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

novobiocin(1-) : An organic anion that is the conjugate base of novobiocin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID54675769
CHEMBL ID36506
CHEBI ID28368
SCHEMBL ID238345
SCHEMBL ID24805
MeSH IDM0015020
PubMed CID15940185
CHEBI ID71339
MeSH IDM0015020

Synonyms (140)

Synonym
BRD-K85307935-236-02-0
DIVK1C_000260
KBIO1_000260
robiocina
SPECTRUM_001001
streptonivicin
coumarin, 7-(4-(carbamoyloxy)tetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamido)-8-methyl-
pa 93
7-(3-(o-carbamoyl)-4-(o-methyl)-5,5-dimethyl-alpha-l-lyxopyranosyloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamidol)-8-methylcumarin
cardelmycin
7-(carbamoyltetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)benzamide)-8-methyl-2h-chromen-2-one
antibiotic pa-93
crystallinic acid
novo-r
ai3-50148
albamix
novobiocina [inn-spanish]
novobiocinum [inn-latin]
stilbiocina
u 6391
hsdb 7443
novobiocine [inn-french]
einecs 206-146-3
benzamide, n-(7-((3-o-(aminocarbonyl)-6-deoxy-5-c-methyl-4-o-methyl-beta-l-lyxo-hexopyranosyl)oxy)-4-hydroxy-8-methyl-2-oxo-2h-1-benzopyran-3-yl)-4-hydroxy-3-(3-methyl-2-butenyl)-
novobiocin [inn:ban]
cathocin
sirbiocina
(3r,4s,5r,6r)-5-hydroxy-6-[(2-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzene]amido}-8-methyl-4-oxo-4h-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyloxan-4-yl carbamate
bdbm282
ACON1_001693
SPECTRUM5_001274
BSPBIO_002115
MEGXM0_000273
CMAP_000043
ACON0_000808
streptonivicin (*sodium salt*)
[(3r,4s,5r,6r)-5-hydroxy-6-[4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-2-oxo-chromen-7-yl]oxy-3-methoxy-2,2-dimethyl-tetrahydropyran-4-yl] carbamate
spheromycin
inamycin
n-[7-[[3-o-(aminocarbonyl)-6-deoxy-5-c-methyl-4-o-methyl-.beta.-l-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2h-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butenyl)
NOV ,
novobiocin
C05080
303-81-1
DB01051
n-{7-[(3-o-carbamoyl-6-deoxy-5-methyl-4-o-methyl-beta-d-gulopyranosyl)oxy]-4-hydroxy-8-methyl-2-oxo-2h-chromen-3-yl}-4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamide
1AJ6
KBIOSS_002407
KBIOGR_002402
KBIOGR_000874
KBIO3_001615
KBIO2_004049
KBIO2_007538
KBIO2_002402
KBIO2_006617
KBIO3_002881
KBIO2_004970
KBIO2_001481
KBIOSS_001481
NINDS_000260
SPECTRUM4_000457
SPECTRUM3_000528
SPECTRUM2_000977
SPBIO_001013
IDI1_000260
(3r,4s,5r,6r)-5-hydroxy-6-{[4-hydroxy-3-({[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]carbonyl}amino)-8-methyl-2-oxo-2h-chromen-7-yl]oxy}-3-methoxy-2,2-dimethyltetrahydro-2h-pyran-4-yl carbamate
carbamic acid (3r,4s,5r,6r)-5-hydroxy-6-{4-hydroxy-3-[4-hydroxy-3-(3-methyl-but-2-enyl)-benzoylamino]-8-methyl-2-oxo-2h-chromen-7-yloxy}-3-methoxy-2,2-dimethyl-tetrahydro-pyran-4-yl ester
(3r,4s,5r,6r)-5-hydroxy-6-(4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)benzamido)-8-methyl-2-oxo-2h-chromen-7-yloxy)-3-methoxy-2,2-dimethyl-tetrahydro-2h-pyran-4-yl carbamate
carbamic acid (3r,4s,5r,6r)-5-hydroxy-6-{4-hydroxy-3-[4-hydroxy-3-(4-methyl-pent-3-enyl)-benzoylamino]-8-methyl-2-oxo-2h-chromen-7-yloxy}-3-methoxy-2,2-dimethyl-tetrahydro-pyran-4-yl ester
(3r,4s,5r,6r)-5-hydroxy-6-(4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)benzamido)-2-oxo-2h-chromen-7-yloxy)-3-methoxy-2,2-dimethyl-tetrahydro-2h-pyran-4-yl carbamate
carbamic acid 5-hydroxy-6-{4-hydroxy-3-[4-hydroxy-3-(3-methyl-but-2-enyl)-benzoylamino]-8-methyl-2-oxo-2h-chromen-7-yloxy}-3-methoxy-2,2-dimethyl-tetrahydro-pyran-4-yl ester
carbamic acid 5-hydroxy-6-{4-hydroxy-3-[4-hydroxy-3-(3-methyl-but-2-enyl)-benzoylamino]-8-methyl-2-oxo-2h-chromen-7-yloxy}-3-methoxy-2,2-dimethyl-tetrahydro-pyran-4-yl ester(novobiocin)
bdbm50226181
chebi:28368 ,
CHEMBL36506 ,
MLS001032086
smr000718617
NCGC00188981-01
unii-17ec19951n
17ec19951n ,
novobiocinum
novobiocine
novobiocina
novobiocin [mi]
novobiocin [inn]
novobiocin [mart.]
novobiocin [usp-rs]
novobiocin [vandf]
novobiocin [who-dd]
novobiocin [hsdb]
benzamide, n-(7-((3-o-(aminocarbonyl)-6-deoxy-5-c-methyl-4-o-methyl-.alpha.-l-lyxo-hexopyranosyl)oxy)-4-hydroxy-8-methyl-2-oxo-2h-1-benzopyran-3-yl)-4-hydroxy-3-(3-methyl-2-buten-1-yl)-
benzamide, n-(7-((3-o-(aminocarbonyl)-6-deoxy-5-c-methyl-4-o-methyl-.beta.-l-lyxo-hexopyranosyl)oxy)-4-hydroxy-8-methyl-2-oxo-2h-1-benzopyran-3-yl)-4-hydroxy-3-(3-methyl-2-butenyl)-
novobiocin [green book]
SCHEMBL238345
A-256
SCHEMBL24805
novobiocin, antibiotic for culture media use only
W-204218
DTXSID3041083 ,
4URN
4URO
(3r,4s,5r,6r)-5-hydroxy-6-[(4-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzene]amido}-8-methyl-2-oxo-2h-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyloxan-4-yl carbamate
(3r,4s,5r,6r)-5-hydroxy-6-(4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)benzamido)-8-methyl-2-oxo-2h-chromen-7-yloxy)-3-methoxy-2,2-dimethyltetrahydro-2h-pyran-4-yl carbamate
AKOS027295139
[(3r,4s,5r,6r)-5-hydroxy-6-[4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-2-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate
Q1639291
(3r,4s,5r,6r)-5-hydroxy-6-((4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamido)-8-methyl-2-oxo-2h-chromen-7-yl)oxy)-3-methoxy-2,2-dimethyltetrahydro-2h-pyran-4-yl carbamate
novobiocin 1000 microg/ml in acetonitrile
EN300-19736048
(3r,4s,5r,6r)-5-hydroxy-6-({4-hydroxy-3-[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamido]-8-methyl-2-oxo-2h-chromen-7-yl}oxy)-3-methoxy-2,2-dimethyloxan-4-yl carbamate
gtpl12021
HY-B0425
CS-0082991
AT38053
novobiocine (inn-french)
novobiocina (inn-spanish)
biotexin
dtxcid1021083
albamix feed medication
novobiocin (mart.)
novobiocinum (inn-latin)
benzamide, n-(7-((3-o-(aminocarbonyl)-6-deoxy-5-c-methyl-4-o-methyl-alpha-l-lyxo-hexopyranosyl)oxy)-4-hydroxy-8-methyl-2-oxo-2h-1-benzopyran-3-yl)-4-hydroxy-3-(3-methyl-2-buten-1-yl)-
novobiocin (usp-rs)
vulkamycin
vulcamicina
novobiocin sodium
UPCMLD-DP066:001 ,
UPCMLD-DP066
NCGC00161630-01
NCGC00161630-02
CHEBI:71339
novobiocin anion
novobiocin(1-)
AB00643367-02
AB00643367_03
AB00053508_02
SBI-0051466.P003
Q27139523
7-[(2r,3r,4s,5r)-4-carbamoyloxy-3-hydroxy-5-methoxy-6,6-dimethyloxan-2-yl]oxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-2-oxochromen-4-olate
n-[7-[[3-o-(aminocarbonyl)-6-deoxy-5-c-methyl-4-o-methyl-alpha-l-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2h-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-buten-1-yl)-benzamide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" NOVO treatment protected tumor cells from Adriamycin (ADR)-induced lethality but sensitized them to the toxic action of 4-hydroperoxycyclophosphamide, and alkylating agent."( Modulation of the cell cycle-dependent cytotoxicity of adriamycin and 4-hydroperoxycyclophosphamide by novobiocin, an inhibitor of mammalian topoisomerase II.
Flannery, DJ; Lee, FY; Siemann, DW, 1992
)
0.28
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" However, any drug with potential for treating diabetic complications must also have no adverse effects on the function of pancreatic islets."( KU-32, a novel drug for diabetic neuropathy, is safe for human islets and improves in vitro insulin secretion and viability.
Blagg, BS; Dobrowsky, R; Farmer, K; Novikova, L; Ramachandran, K; Rawal, S; Stehno-Bittel, L; Williams, SJ, 2012
)
0.38

Pharmacokinetics

ExcerptReferenceRelevance
" The biliary excretion, intestinal damage, and pharmacokinetic study of CPT-11-loaded PEO-PPO-PEO micelles were investigated in rats."( Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
Gan, L; Gan, Y; Guo, S; Zhang, X; Zhu, C, 2010
)
0.36

Compound-Compound Interactions

Novobiocin may be given with high-dose alkylators in doses that produce plasma levels that augment the activity of these cytotoxics in experimental models.

ExcerptReferenceRelevance
" This trial was performed to determine if novobiocin, an agent that inhibits DNA repair, could be given with high-dose alkylators."( Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.
Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995
)
0.29
"Novobiocin may be given with high-dose alkylators in doses that produce plasma levels that augment the activity of these cytotoxics in experimental models."( Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.
Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995
)
0.29
"The in vitro activity of DU-6859a (DU) alone and in combination with various antimicrobials was evaluated against multiresistant enterococci including some isolates with defined gyrA mutations."( Bactericidal activity of the fluoroquinolone DU-6859a alone and in combination with other antimicrobial agents against multiresistant enterococci.
Erdem, I; Korten, V; Murray, BE, 1996
)
0.29
" Therefore, we conducted a clinical trial to determine the maximum tolerated dose and the pharmacokinetics of novobiocin when given in combination with VP-16."( Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies.
DiStasio, SA; Egorin, MJ; Lorico, A; McKeon, A; Murren, JR; Rappa, G; Sartorelli, AC; Zuhowski, EG,
)
0.13
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" Treatment with PEO-PPO-PEO micelles resulted in prolonged circulation time in blood and increased bioavailability of CPT-11 and SN-38 (7-ethyl-10-hydroxycamptothecin)."( Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
Gan, L; Gan, Y; Guo, S; Zhang, X; Zhu, C, 2010
)
0.36
" The measured oral bioavailability of compound B was 47."( Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
Barker, S; Bennett, JM; Berry, J; Collins, I; Czaplewski, LG; Gamble, V; Haydon, DJ; Lancett, P; Logan, A; Lunniss, CJ; Peasley, H; Pommier, S; Price, D; Smee, C; Stokes, NR; Thomaides-Brears, HB, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Thirty-six patients were entered on a Phase II trial using high-dose cisplatin (100 mg/m2 on days 1 and 8 for four cycles) after steady-state dosing with novobiocin (1000 mg or four 250-mg capsules every 12 hours for six doses, four of which were administered before each dose of cisplatin)."( Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A Southwest Oncology Group study.
Allen, A; Crowley, J; Ellis, GK; Goodwin, JW; Hutchins, L; Livingston, RB, 1991
)
0.28
" Here we report dose-response data on the mutagenicity and toxicity of m-AMSA in T4 rFC11."( Mutagenicity of topoisomerase-active agents in bacteriophage T4.
DeMarini, DM; Lawrence, BK, 1988
)
0.27
"5:1; the ratio in serum of patients dosed with Panalba) showed a significant retardation of resistance outgrowth compared with subculture in the presence of the antibiotics individually."( Development of resistance to novobiocin, tetracycline, and a novobiocin-tetracycline combination in Staphylococcus aureus populations.
Vavra, JJ, 1967
)
0.25
" The three inhibitors all yielded anomalous dose-response curves, indicating that the four molecular species have different inhibitory potentials."( The amphiphilic properties of novenamines determine their activity as inhibitors of HIV-1 RNase H.
Althaus, IW; Buxser, SE; Decker, DE; Dolak, LA; Franks, KM; Kézdy, FJ; Langley, KB; Peterson, T; Reusser, F; Ulrich, RG, 1996
)
0.29
" A high drug exposure NOEL on oral dosing in the rat suggested that a high therapeutic margin could be achieved."( Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.
Basarab, GS; Brassil, P; Doig, P; Galullo, V; Gowravaram, M; Haimes, HB; Kern, G; Kutschke, A; McNulty, J; Schuck, VJ; Stone, G, 2014
)
0.4
"9-fold, respectively, in rats, whereas its systemic clearance following intravenous dosing was not influenced."( Usefulness of novobiocin as a selective inhibitor of intestinal breast cancer resistance protein (Bcrp) in rats.
Aoyama, T; Suzuki, K; Taniyama, K; Watanabe, Y, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitorA topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
hepatoprotective agentAny compound that is able to prevent damage to the liver.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (8)

ClassDescription
hexoside
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
hydroxycoumarinAny coumarin carrying at least one hydroxy substituent.
etherAn organooxygen compound with formula ROR, where R is not hydrogen.
carbamate esterAny ester of carbamic acid or its N-substituted derivatives.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
organic anionAny organic ion with a net negative charge.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
novobiocin biosynthesis1741

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.01000.003245.467312,589.2998AID2517
PPM1D proteinHomo sapiens (human)Potency20.82120.00529.466132.9993AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency4.64440.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency19.95260.035520.977089.1251AID504332
Interferon betaHomo sapiens (human)Potency20.82120.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein Zika virusIC50 (µMol)14.20001.10001.94004.1000AID1659175
DNA gyrase subunit BMycolicibacterium smegmatis MC2 155IC50 (µMol)0.04600.04600.04600.0460AID1326670
Heat shock protein HSP 90-betaHomo sapiens (human)IC50 (µMol)231.00000.00100.683610.0000AID1181926
DNA gyrase subunit BStaphylococcus aureusIC50 (µMol)0.04740.00401.50207.7000AID1167976; AID1167977; AID1233796; AID1233815; AID1303168; AID1303183; AID1323396; AID1359999; AID1446677; AID1459321; AID1482527; AID1520485; AID1576139; AID1671924; AID1678526; AID1756500; AID1801385; AID1801386; AID717074
DNA gyrase subunit BStaphylococcus aureusKi0.03600.01000.03600.1100AID1798447; AID363427
DNA gyrase subunit BStreptococcus pneumoniae TIGR4IC50 (µMol)0.03700.03700.03700.0370AID446852
DNA gyrase subunit AEscherichia coli K-12IC50 (µMol)0.14410.02390.56295.2300AID1233794; AID1233816; AID1415761; AID1415762; AID1576137; AID1671927; AID1678525; AID1698680; AID1756499; AID520090
DNA gyrase subunit AEscherichia coli K-12Ki0.04470.01000.04470.1100AID1798447
DNA gyrase subunit BEscherichia coli K-12IC50 (µMol)0.15370.00500.43985.2300AID1233794; AID1233816; AID1323395; AID1359990; AID1415761; AID1415762; AID1459318; AID1576137; AID1671927; AID1678525; AID1698680; AID1756499; AID520090; AID529382; AID529383
DNA gyrase subunit BEscherichia coli K-12Ki0.03520.00700.03520.1100AID1335285; AID1798447
DNA topoisomerase 4 subunit AEscherichia coli K-12Ki0.04470.01000.04470.1100AID1798447
DNA topoisomerase 4 subunit BStaphylococcus aureusIC50 (µMol)22.65000.55006.68719.1600AID1233800; AID1233813; AID1576143; AID1671920; AID1678530; AID1688284
DNA topoisomerase 4 subunit AStaphylococcus aureusIC50 (µMol)25.60000.30003.55799.1600AID1233800; AID1233813; AID1576143; AID1671920; AID1678530
DNA gyrase subunit BMycolicibacterium smegmatisIC50 (µMol)25.85230.04600.16100.2000AID1054860; AID1173783; AID1188153; AID1193921; AID1194330; AID1252459; AID1335283
DNA topoisomerase 2-alphaHomo sapiens (human)IC50 (µMol)256.00000.48004.35649.9400AID1482554
Heat shock protein HSP 90Oryctolagus cuniculus (rabbit)IC50 (µMol)382.00000.28201.14102.0000AID1181925; AID595269
Angiotensin-converting enzyme Homo sapiens (human)Ki167.00000.00000.82557.5000AID1053270
DNA topoisomerase 4 subunit BEscherichia coli K-12Ki0.04470.01000.04470.1100AID1798447
DNA gyrase subunit AStaphylococcus aureusIC50 (µMol)0.03830.00401.98397.7000AID1167977; AID1233796; AID1233815; AID1303168; AID1303183; AID1446677; AID1482527; AID1520485; AID1576139; AID1671924; AID1678526; AID1756500; AID717074
DNA gyrase subunit AStaphylococcus aureusKi0.03600.01000.03600.1100AID1798447; AID363427
DNA gyrase subunit BMycobacterium tuberculosis H37RvIC50 (µMol)4.22240.01502.467610.0000AID1054854; AID1164298; AID1173784; AID1188154; AID1194333; AID1252462; AID1266236; AID1272956; AID1335284; AID1399853; AID1399854
DNA gyrase subunit AMycobacterium tuberculosis H37RvIC50 (µMol)3.95380.01503.477310.0000AID1054854; AID1164298; AID1173784; AID1188154; AID1194333; AID1252462; AID1266236; AID1272956; AID1335284; AID1399853; AID1399854; AID1799875
DNA topoisomerase Streptococcus pneumoniaeIC50 (µMol)2.03002.03002.03002.0300AID446853
Microtubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)Ki19.30008.10008.10008.1000AID1775857
Microtubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)Ki8.80003.30006.05008.8000AID1775854
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)61.39390.00401.966610.0000AID1873195; AID364887; AID451987; AID451988; AID679622
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, GyraseEscherichia coliKd1.20001.20001.20001.2000AID977611
Genome polyprotein Zika virusEC50 (µMol)24.80000.02200.30730.6000AID1659178
AlbuminHomo sapiens (human)Kd12.00000.08933.31358.0000AID557095
Heat shock protein HSP 90-alphaHomo sapiens (human)EC50 (µMol)700.00000.00400.13311.2000AID1666221
Heat shock protein HSP 90-alphaHomo sapiens (human)Kd500.00000.00030.94889.8000AID1726505
Heat shock protein HSP 90-betaHomo sapiens (human)EC50 (µMol)700.00000.00400.23851.7000AID1666221
Heat shock protein HSP 90-betaHomo sapiens (human)Kd500.00000.00031.33309.8000AID1726505
DNA gyrase subunit BEscherichia coli K-12Kd0.01750.00120.01210.0280AID1335277; AID704336
Microtubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)Kd7.50002.80005.15007.5000AID1775855
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interferon gamma precursorHomo sapiens (human)AC5020.14000.128015.173038.6100AID1259418; AID1259420
Heat shock protein HSP 90-betaHomo sapiens (human)Activity700.00000.05000.53371.2700AID595164
DNA gyrase subunit BStaphylococcus aureusMIC0.01000.01000.01000.0100AID1245290
DNA gyrase subunit AEscherichia coli K-12Activity3.10000.28001.71603.2000AID529385
Cell division inhibitor SulAEscherichia coli K-12Activity6.30001.00003.65006.3000AID529386
DNA gyrase subunit AStaphylococcus aureusMIC0.01000.01000.01000.0100AID1245290
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (199)

Processvia Protein(s)Taxonomy
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
telomere maintenance via telomeraseHeat shock protein HSP 90-alphaHomo sapiens (human)
neuron migrationHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of protein phosphorylationHeat shock protein HSP 90-alphaHomo sapiens (human)
activation of innate immune responseHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of defense response to virus by hostHeat shock protein HSP 90-alphaHomo sapiens (human)
skeletal muscle contractionHeat shock protein HSP 90-alphaHomo sapiens (human)
mitochondrial transportHeat shock protein HSP 90-alphaHomo sapiens (human)
response to unfolded proteinHeat shock protein HSP 90-alphaHomo sapiens (human)
response to heatHeat shock protein HSP 90-alphaHomo sapiens (human)
response to coldHeat shock protein HSP 90-alphaHomo sapiens (human)
response to xenobiotic stimulusHeat shock protein HSP 90-alphaHomo sapiens (human)
response to salt stressHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of lamellipodium assemblyHeat shock protein HSP 90-alphaHomo sapiens (human)
cardiac muscle cell apoptotic processHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of protein ubiquitinationHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of protein polymerizationHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of interferon-beta productionHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of protein localizationHeat shock protein HSP 90-alphaHomo sapiens (human)
protein refoldingHeat shock protein HSP 90-alphaHomo sapiens (human)
response to cocaineHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of protein import into nucleusHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of apoptotic processHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of protein-containing complex assemblyHeat shock protein HSP 90-alphaHomo sapiens (human)
protein unfoldingHeat shock protein HSP 90-alphaHomo sapiens (human)
response to estrogenHeat shock protein HSP 90-alphaHomo sapiens (human)
protein insertion into mitochondrial outer membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of protein catabolic processHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of cell sizeHeat shock protein HSP 90-alphaHomo sapiens (human)
response to antibioticHeat shock protein HSP 90-alphaHomo sapiens (human)
protein stabilizationHeat shock protein HSP 90-alphaHomo sapiens (human)
chaperone-mediated protein complex assemblyHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of cardiac muscle contractionHeat shock protein HSP 90-alphaHomo sapiens (human)
chaperone-mediated autophagyHeat shock protein HSP 90-alphaHomo sapiens (human)
cellular response to virusHeat shock protein HSP 90-alphaHomo sapiens (human)
regulation of postsynaptic membrane neurotransmitter receptor levelsHeat shock protein HSP 90-alphaHomo sapiens (human)
positive regulation of tau-protein kinase activityHeat shock protein HSP 90-alphaHomo sapiens (human)
telomerase holoenzyme complex assemblyHeat shock protein HSP 90-alphaHomo sapiens (human)
cellular response to heatHeat shock protein HSP 90-alphaHomo sapiens (human)
protein foldingHeat shock protein HSP 90-alphaHomo sapiens (human)
telomere maintenance via telomeraseHeat shock protein HSP 90-betaHomo sapiens (human)
placenta developmentHeat shock protein HSP 90-betaHomo sapiens (human)
response to unfolded proteinHeat shock protein HSP 90-betaHomo sapiens (human)
virion attachment to host cellHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayHeat shock protein HSP 90-betaHomo sapiens (human)
regulation of protein ubiquitinationHeat shock protein HSP 90-betaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activityHeat shock protein HSP 90-betaHomo sapiens (human)
regulation of protein localizationHeat shock protein HSP 90-betaHomo sapiens (human)
negative regulation of apoptotic processHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of cell differentiationHeat shock protein HSP 90-betaHomo sapiens (human)
chaperone-mediated protein complex assemblyHeat shock protein HSP 90-betaHomo sapiens (human)
regulation of cell cycleHeat shock protein HSP 90-betaHomo sapiens (human)
chaperone-mediated protein foldingHeat shock protein HSP 90-betaHomo sapiens (human)
cellular response to interleukin-4Heat shock protein HSP 90-betaHomo sapiens (human)
supramolecular fiber organizationHeat shock protein HSP 90-betaHomo sapiens (human)
negative regulation of proteasomal protein catabolic processHeat shock protein HSP 90-betaHomo sapiens (human)
telomerase holoenzyme complex assemblyHeat shock protein HSP 90-betaHomo sapiens (human)
positive regulation of protein localization to cell surfaceHeat shock protein HSP 90-betaHomo sapiens (human)
cellular response to heatHeat shock protein HSP 90-betaHomo sapiens (human)
protein foldingHeat shock protein HSP 90-betaHomo sapiens (human)
protein stabilizationHeat shock protein HSP 90-betaHomo sapiens (human)
DNA topological changeDNA gyrase subunit AEscherichia coli K-12
DNA-templated transcriptionDNA gyrase subunit AEscherichia coli K-12
response to xenobiotic stimulusDNA gyrase subunit AEscherichia coli K-12
DNA-templated DNA replicationDNA gyrase subunit AEscherichia coli K-12
DNA topological changeDNA gyrase subunit AEscherichia coli K-12
response to antibioticDNA gyrase subunit AEscherichia coli K-12
chromosome organizationDNA gyrase subunit AEscherichia coli K-12
negative regulation of DNA-templated DNA replicationDNA gyrase subunit AEscherichia coli K-12
DNA topological changeDNA gyrase subunit BEscherichia coli K-12
DNA-templated transcriptionDNA gyrase subunit BEscherichia coli K-12
response to xenobiotic stimulusDNA gyrase subunit BEscherichia coli K-12
DNA-templated DNA replicationDNA gyrase subunit BEscherichia coli K-12
DNA topological changeDNA gyrase subunit BEscherichia coli K-12
response to antibioticDNA gyrase subunit BEscherichia coli K-12
chromosome organizationDNA gyrase subunit BEscherichia coli K-12
DNA topological changeDNA topoisomerase 4 subunit AEscherichia coli K-12
chromosome segregationDNA topoisomerase 4 subunit AEscherichia coli K-12
sister chromatid cohesionDNA topoisomerase 4 subunit AEscherichia coli K-12
plasmid partitioningDNA topoisomerase 4 subunit AEscherichia coli K-12
DNA topological changeDNA topoisomerase 4 subunit AEscherichia coli K-12
chromosome segregationDNA topoisomerase 4 subunit AEscherichia coli K-12
chromosome organizationDNA topoisomerase 4 subunit AEscherichia coli K-12
DNA damage responseCell division inhibitor SulAEscherichia coli K-12
SOS responseCell division inhibitor SulAEscherichia coli K-12
negative regulation of protein polymerizationCell division inhibitor SulAEscherichia coli K-12
negative regulation of cytokinesisCell division inhibitor SulAEscherichia coli K-12
negative regulation of cell divisionCell division inhibitor SulAEscherichia coli K-12
negative regulation of FtsZ-dependent cytokinesisCell division inhibitor SulAEscherichia coli K-12
division septum assemblyCell division inhibitor SulAEscherichia coli K-12
SOS responseCell division inhibitor SulAEscherichia coli K-12
negative regulation of cytokinesisCell division inhibitor SulAEscherichia coli K-12
cell divisionCell division inhibitor SulAEscherichia coli K-12
negative regulation of cell divisionCell division inhibitor SulAEscherichia coli K-12
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
response to hypoxiaAngiotensin-converting enzyme Homo sapiens (human)
kidney developmentAngiotensin-converting enzyme Homo sapiens (human)
blood vessel remodelingAngiotensin-converting enzyme Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme Homo sapiens (human)
regulation of renal output by angiotensinAngiotensin-converting enzyme Homo sapiens (human)
neutrophil mediated immunityAngiotensin-converting enzyme Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IAngiotensin-converting enzyme Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme Homo sapiens (human)
proteolysisAngiotensin-converting enzyme Homo sapiens (human)
spermatogenesisAngiotensin-converting enzyme Homo sapiens (human)
female pregnancyAngiotensin-converting enzyme Homo sapiens (human)
regulation of blood pressureAngiotensin-converting enzyme Homo sapiens (human)
male gonad developmentAngiotensin-converting enzyme Homo sapiens (human)
response to xenobiotic stimulusAngiotensin-converting enzyme Homo sapiens (human)
embryo development ending in birth or egg hatchingAngiotensin-converting enzyme Homo sapiens (human)
post-transcriptional regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
substance P catabolic processAngiotensin-converting enzyme Homo sapiens (human)
bradykinin catabolic processAngiotensin-converting enzyme Homo sapiens (human)
regulation of smooth muscle cell migrationAngiotensin-converting enzyme Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
animal organ regenerationAngiotensin-converting enzyme Homo sapiens (human)
response to nutrient levelsAngiotensin-converting enzyme Homo sapiens (human)
response to lipopolysaccharideAngiotensin-converting enzyme Homo sapiens (human)
mononuclear cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
response to laminar fluid shear stressAngiotensin-converting enzyme Homo sapiens (human)
angiotensin-activated signaling pathwayAngiotensin-converting enzyme Homo sapiens (human)
vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
hormone metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hormone catabolic processAngiotensin-converting enzyme Homo sapiens (human)
eating behaviorAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of apoptotic processAngiotensin-converting enzyme Homo sapiens (human)
peptide catabolic processAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of glucose importAngiotensin-converting enzyme Homo sapiens (human)
regulation of synaptic plasticityAngiotensin-converting enzyme Homo sapiens (human)
lung alveolus developmentAngiotensin-converting enzyme Homo sapiens (human)
amyloid-beta metabolic processAngiotensin-converting enzyme Homo sapiens (human)
arachidonic acid secretionAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of neurogenesisAngiotensin-converting enzyme Homo sapiens (human)
heart contractionAngiotensin-converting enzyme Homo sapiens (human)
regulation of angiotensin metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hematopoietic stem cell differentiationAngiotensin-converting enzyme Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisAngiotensin-converting enzyme Homo sapiens (human)
cellular response to glucose stimulusAngiotensin-converting enzyme Homo sapiens (human)
response to dexamethasoneAngiotensin-converting enzyme Homo sapiens (human)
cell proliferation in bone marrowAngiotensin-converting enzyme Homo sapiens (human)
regulation of heart rate by cardiac conductionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of calcium ion importAngiotensin-converting enzyme Homo sapiens (human)
response to thyroid hormoneAngiotensin-converting enzyme Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme Homo sapiens (human)
regulation of hematopoietic stem cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gap junction assemblyAngiotensin-converting enzyme Homo sapiens (human)
cellular response to aldosteroneAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylationAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of systemic arterial blood pressureAngiotensin-converting enzyme Homo sapiens (human)
sister chromatid cohesionDNA topoisomerase 4 subunit BEscherichia coli K-12
plasmid partitioningDNA topoisomerase 4 subunit BEscherichia coli K-12
chromosome organizationDNA topoisomerase 4 subunit BEscherichia coli K-12
DNA topological changeDNA topoisomerase 4 subunit BEscherichia coli K-12
chromosome segregationDNA topoisomerase 4 subunit BEscherichia coli K-12
response to antibioticDNA topoisomerase 4 subunit BEscherichia coli K-12
chromosome organizationDNA topoisomerase 4 subunit BEscherichia coli K-12
autophagosome assemblyMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
mitophagyMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
autophagyMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
cellular response to starvationMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
macroautophagyMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
autophagosome maturationMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
autophagy of mitochondrionMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
cellular response to nitrogen starvationMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
autophagy of mitochondrionMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
autophagosome assemblyMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
JNK cascadeMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
cellular response to starvationMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
response to iron(II) ionMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
response to lead ionMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
macroautophagyMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
cellular response to amino acid starvationMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
p38MAPK cascadeMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
SMAD protein signal transductionMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
cellular response to hydrogen peroxideMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
cellular response to copper ionMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
cellular response to oxygen-glucose deprivationMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
autophagosome maturationMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
autophagy of mitochondrionMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
cellular response to nitrogen starvationMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (94)

Processvia Protein(s)Taxonomy
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
UTP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
CTP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
RNA bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
mRNA bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
ATP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
GTP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
ATP hydrolysis activityHeat shock protein HSP 90-alphaHomo sapiens (human)
sulfonylurea receptor bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
protein phosphatase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
MHC class II protein complex bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
nitric-oxide synthase regulator activityHeat shock protein HSP 90-alphaHomo sapiens (human)
TPR domain bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
ubiquitin protein ligase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
dATP bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
identical protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
protein homodimerization activityHeat shock protein HSP 90-alphaHomo sapiens (human)
histone deacetylase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
transmembrane transporter bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
tau protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
GTPase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
Rho GDP-dissociation inhibitor bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
DNA polymerase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
scaffold protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
disordered domain specific bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
ATP-dependent protein folding chaperoneHeat shock protein HSP 90-alphaHomo sapiens (human)
protein tyrosine kinase bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
unfolded protein bindingHeat shock protein HSP 90-alphaHomo sapiens (human)
RNA bindingHeat shock protein HSP 90-betaHomo sapiens (human)
double-stranded RNA bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ATP bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ATP hydrolysis activityHeat shock protein HSP 90-betaHomo sapiens (human)
protein kinase regulator activityHeat shock protein HSP 90-betaHomo sapiens (human)
kinase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein kinase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
MHC class II protein complex bindingHeat shock protein HSP 90-betaHomo sapiens (human)
nitric-oxide synthase regulator activityHeat shock protein HSP 90-betaHomo sapiens (human)
TPR domain bindingHeat shock protein HSP 90-betaHomo sapiens (human)
heat shock protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ubiquitin protein ligase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
peptide bindingHeat shock protein HSP 90-betaHomo sapiens (human)
identical protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein homodimerization activityHeat shock protein HSP 90-betaHomo sapiens (human)
histone deacetylase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ATP-dependent protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein folding chaperoneHeat shock protein HSP 90-betaHomo sapiens (human)
cadherin bindingHeat shock protein HSP 90-betaHomo sapiens (human)
protein dimerization activityHeat shock protein HSP 90-betaHomo sapiens (human)
tau protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
DNA polymerase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
disordered domain specific bindingHeat shock protein HSP 90-betaHomo sapiens (human)
ATP-dependent protein folding chaperoneHeat shock protein HSP 90-betaHomo sapiens (human)
receptor ligand inhibitor activityHeat shock protein HSP 90-betaHomo sapiens (human)
histone methyltransferase bindingHeat shock protein HSP 90-betaHomo sapiens (human)
unfolded protein bindingHeat shock protein HSP 90-betaHomo sapiens (human)
DNA bindingDNA gyrase subunit AEscherichia coli K-12
DNA topoisomerase activityDNA gyrase subunit AEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA gyrase subunit AEscherichia coli K-12
protein bindingDNA gyrase subunit AEscherichia coli K-12
ATP bindingDNA gyrase subunit AEscherichia coli K-12
ATP-dependent activity, acting on DNADNA gyrase subunit AEscherichia coli K-12
DNA negative supercoiling activityDNA gyrase subunit AEscherichia coli K-12
identical protein bindingDNA gyrase subunit AEscherichia coli K-12
DNA bindingDNA gyrase subunit BEscherichia coli K-12
DNA topoisomerase activityDNA gyrase subunit BEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA gyrase subunit BEscherichia coli K-12
protein bindingDNA gyrase subunit BEscherichia coli K-12
ATP bindingDNA gyrase subunit BEscherichia coli K-12
ATP-dependent activity, acting on DNADNA gyrase subunit BEscherichia coli K-12
DNA negative supercoiling activityDNA gyrase subunit BEscherichia coli K-12
metal ion bindingDNA gyrase subunit BEscherichia coli K-12
DNA topoisomerase activityDNA topoisomerase 4 subunit AEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 4 subunit AEscherichia coli K-12
DNA bindingDNA topoisomerase 4 subunit AEscherichia coli K-12
DNA topoisomerase activityDNA topoisomerase 4 subunit AEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 4 subunit AEscherichia coli K-12
protein bindingDNA topoisomerase 4 subunit AEscherichia coli K-12
ATP bindingDNA topoisomerase 4 subunit AEscherichia coli K-12
protein bindingCell division inhibitor SulAEscherichia coli K-12
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metalloendopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
calmodulin bindingAngiotensin-converting enzyme Homo sapiens (human)
peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
exopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
tripeptidyl-peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme Homo sapiens (human)
chloride ion bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
bradykinin receptor bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
metallodipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
heterocyclic compound bindingAngiotensin-converting enzyme Homo sapiens (human)
DNA bindingDNA topoisomerase 4 subunit BEscherichia coli K-12
DNA topoisomerase activityDNA topoisomerase 4 subunit BEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 4 subunit BEscherichia coli K-12
protein bindingDNA topoisomerase 4 subunit BEscherichia coli K-12
ATP bindingDNA topoisomerase 4 subunit BEscherichia coli K-12
metal ion bindingDNA topoisomerase 4 subunit BEscherichia coli K-12
protein bindingMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
phosphatidylethanolamine bindingMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
ubiquitin protein ligase bindingMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
ceramide bindingMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
microtubule bindingMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
protein bindingMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
phospholipid bindingMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
ubiquitin protein ligase bindingMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
microtubule bindingMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
phosphatidylethanolamine bindingMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (67)

Processvia Protein(s)Taxonomy
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
extracellular regionHeat shock protein HSP 90-alphaHomo sapiens (human)
nucleusHeat shock protein HSP 90-alphaHomo sapiens (human)
nucleoplasmHeat shock protein HSP 90-alphaHomo sapiens (human)
cytoplasmHeat shock protein HSP 90-alphaHomo sapiens (human)
mitochondrionHeat shock protein HSP 90-alphaHomo sapiens (human)
cytosolHeat shock protein HSP 90-alphaHomo sapiens (human)
plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
cell surfaceHeat shock protein HSP 90-alphaHomo sapiens (human)
membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
basolateral plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
apical plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
brush border membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
secretory granule lumenHeat shock protein HSP 90-alphaHomo sapiens (human)
melanosomeHeat shock protein HSP 90-alphaHomo sapiens (human)
neuronal cell bodyHeat shock protein HSP 90-alphaHomo sapiens (human)
lysosomal lumenHeat shock protein HSP 90-alphaHomo sapiens (human)
dendritic growth coneHeat shock protein HSP 90-alphaHomo sapiens (human)
axonal growth coneHeat shock protein HSP 90-alphaHomo sapiens (human)
perinuclear region of cytoplasmHeat shock protein HSP 90-alphaHomo sapiens (human)
collagen-containing extracellular matrixHeat shock protein HSP 90-alphaHomo sapiens (human)
extracellular exosomeHeat shock protein HSP 90-alphaHomo sapiens (human)
endocytic vesicle lumenHeat shock protein HSP 90-alphaHomo sapiens (human)
sperm mitochondrial sheathHeat shock protein HSP 90-alphaHomo sapiens (human)
sperm plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
ficolin-1-rich granule lumenHeat shock protein HSP 90-alphaHomo sapiens (human)
protein-containing complexHeat shock protein HSP 90-alphaHomo sapiens (human)
plasma membraneHeat shock protein HSP 90-alphaHomo sapiens (human)
neuronal cell bodyHeat shock protein HSP 90-alphaHomo sapiens (human)
perinuclear region of cytoplasmHeat shock protein HSP 90-alphaHomo sapiens (human)
myelin sheathHeat shock protein HSP 90-alphaHomo sapiens (human)
cytosolHeat shock protein HSP 90-alphaHomo sapiens (human)
nucleusHeat shock protein HSP 90-alphaHomo sapiens (human)
COP9 signalosomeHeat shock protein HSP 90-betaHomo sapiens (human)
protein folding chaperone complexHeat shock protein HSP 90-betaHomo sapiens (human)
extracellular regionHeat shock protein HSP 90-betaHomo sapiens (human)
nucleusHeat shock protein HSP 90-betaHomo sapiens (human)
nucleoplasmHeat shock protein HSP 90-betaHomo sapiens (human)
cytoplasmHeat shock protein HSP 90-betaHomo sapiens (human)
mitochondrionHeat shock protein HSP 90-betaHomo sapiens (human)
cytosolHeat shock protein HSP 90-betaHomo sapiens (human)
cell surfaceHeat shock protein HSP 90-betaHomo sapiens (human)
membraneHeat shock protein HSP 90-betaHomo sapiens (human)
secretory granule lumenHeat shock protein HSP 90-betaHomo sapiens (human)
melanosomeHeat shock protein HSP 90-betaHomo sapiens (human)
neuronal cell bodyHeat shock protein HSP 90-betaHomo sapiens (human)
dendritic growth coneHeat shock protein HSP 90-betaHomo sapiens (human)
axonal growth coneHeat shock protein HSP 90-betaHomo sapiens (human)
perinuclear region of cytoplasmHeat shock protein HSP 90-betaHomo sapiens (human)
extracellular exosomeHeat shock protein HSP 90-betaHomo sapiens (human)
dynein axonemal particleHeat shock protein HSP 90-betaHomo sapiens (human)
ficolin-1-rich granule lumenHeat shock protein HSP 90-betaHomo sapiens (human)
protein-containing complexHeat shock protein HSP 90-betaHomo sapiens (human)
aryl hydrocarbon receptor complexHeat shock protein HSP 90-betaHomo sapiens (human)
HSP90-CDC37 chaperone complexHeat shock protein HSP 90-betaHomo sapiens (human)
perinuclear region of cytoplasmHeat shock protein HSP 90-betaHomo sapiens (human)
plasma membraneHeat shock protein HSP 90-betaHomo sapiens (human)
cytosolHeat shock protein HSP 90-betaHomo sapiens (human)
chromosomeDNA gyrase subunit AEscherichia coli K-12
cytoplasmDNA gyrase subunit AEscherichia coli K-12
cytosolDNA gyrase subunit AEscherichia coli K-12
membraneDNA gyrase subunit AEscherichia coli K-12
cytoplasmDNA gyrase subunit AEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA gyrase subunit AEscherichia coli K-12
chromosomeDNA gyrase subunit BEscherichia coli K-12
cytoplasmDNA gyrase subunit BEscherichia coli K-12
cytosolDNA gyrase subunit BEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA gyrase subunit BEscherichia coli K-12
chromosomeDNA topoisomerase 4 subunit AEscherichia coli K-12
cytoplasmDNA topoisomerase 4 subunit AEscherichia coli K-12
cytosolDNA topoisomerase 4 subunit AEscherichia coli K-12
plasma membraneDNA topoisomerase 4 subunit AEscherichia coli K-12
extrinsic component of plasma membraneDNA topoisomerase 4 subunit AEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 4 subunit AEscherichia coli K-12
cytoplasmDNA topoisomerase 4 subunit AEscherichia coli K-12
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
lysosomeAngiotensin-converting enzyme Homo sapiens (human)
endosomeAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
external side of plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
basal plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme Homo sapiens (human)
sperm midpieceAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
chromosomeDNA topoisomerase 4 subunit BEscherichia coli K-12
cytosolDNA topoisomerase 4 subunit BEscherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 4 subunit BEscherichia coli K-12
autophagosome membraneMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
mitochondrionMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
autophagosomeMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
cytosolMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
microtubuleMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
axonemeMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
endomembrane systemMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
organelle membraneMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
cytoplasmic vesicleMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
mitochondrial membraneMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
intracellular membrane-bounded organelleMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
autophagosome membraneMicrotubule-associated proteins 1A/1B light chain 3BHomo sapiens (human)
autophagosome membraneMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
late endosomeMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
autophagosomeMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
cytosolMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
microtubuleMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
organelle membraneMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
intracellular membrane-bounded organelleMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
autolysosomeMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
glutamatergic synapseMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
autophagosome membraneMicrotubule-associated proteins 1A/1B light chain 3AHomo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1013)

Assay IDTitleYearJournalArticle
AID1798447DNA Gyrase ATPase Assay from Article 10.1021/jm800318d: \\Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structur2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
AID1801385GyraseB Assay from Article 10.1111/cbdd.12529: \\Design and Biological Evaluation of Furan/Pyrrole/Thiophene-2-carboxamide Derivatives as Efficient DNA GyraseB Inhibitors of Staphylococcus aureus.\\2015Chemical biology & drug design, Oct, Volume: 86, Issue:4
Design and Biological Evaluation of Furan/Pyrrole/Thiophene-2-carboxamide Derivatives as Efficient DNA GyraseB Inhibitors of Staphylococcus aureus.
AID1801386Supercoiling Assay from Article 10.1111/cbdd.12529: \\Design and Biological Evaluation of Furan/Pyrrole/Thiophene-2-carboxamide Derivatives as Efficient DNA GyraseB Inhibitors of Staphylococcus aureus.\\2015Chemical biology & drug design, Oct, Volume: 86, Issue:4
Design and Biological Evaluation of Furan/Pyrrole/Thiophene-2-carboxamide Derivatives as Efficient DNA GyraseB Inhibitors of Staphylococcus aureus.
AID1799553Binding Assay from Article 10.1016/j.chembiol.2011.02.011: \\Sequential mechanism of assembly of multidrug efflux pump AcrAB-TolC.\\2011Chemistry & biology, Apr-22, Volume: 18, Issue:4
Sequential mechanism of assembly of multidrug efflux pump AcrAB-TolC.
AID308454Antibacterial activity against Staphylococcus aureus UC9218 in presence of 5% HSA2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
Structure-activity relationships of bioisosteres of a carboxylic acid in a novel class of bacterial translation inhibitors.
AID1359991Inhibition of Escherichia coli C-terminal His6-tagged topoisomerase-4 expressed in Escherichia coli BL21(DE3) preincubated for 10 mins followed by ATP addition measured after 30 mins by purine nucleoside phosphorylase enzyme coupled spectrophotometric met2018European journal of medicinal chemistry, Jun-25, Volume: 154New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
AID308993Antibacterial activity against erythromycin, methicillin and trimethoprim-resistant Staphylococcus aureus Smith 744 by twofold agar dilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors.
AID524391Antibacterial activity against Escherichia coli NKE1368 harboring deletion mutation in acrB, acrD and vector expressing mdtABC gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID571927Ratio of MIC for Escherichia coli K-12 3-AG300 harboring acrB::rpsLneo mutant gene to MIC for Escherichia coli K-12 3-AG3002009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID564983Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring pPAZ23 carrying p27-p55 operon by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID557091Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 4% human serum albumin2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1233800Inhibition of Staphylococcus aureus DNA topoisomerase 4 using relaxed pNO1 plasmid and biotinylated oligonucelotide incubated for 30 mins by fluorescence based DNA relaxation assay2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.
AID717068Antibacterial activity against coumermycin A1-resistant Staphylococcus aureus MB 5957/H7 harboring GyrB Gln136Glu, Ile175Thr, Leu455Ile mutant2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID354538Cytotoxicity against rat C6 cells at 50 ug/mL to 2.5 mg/mL after 3 days treated 4 hrs before db-cAMP challenge by MTT assay1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID205564Minimum inhibitory concentration against Staphylococcus aureus ATCC 259232004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID68236In vitro antibacterial activity against Enterococcus faecium 02D31P2 VanTeiEry-R1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B.
AID571763Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-F628F mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID1482549Inhibition of fluoroquinolone-resistant Streptococcus pneumoniae A-70 clinical isolate DNA gyrase subunit GyrB/GyrA S81F mutant supercoiling activity using relaxed pBR322 DNA as substrate after 1 hr mins by agarose gel electrophoresis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID1576137Inhibition of Escherichia coli DNA gyrase using relaxed pNO1 plasmid DNA as substrate incubated for 30 mins by fluorescence assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
New
AID205820Compound was tested in vitro for antibacterial activity against Staphylococcus aureus Smith QR-542000Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8
Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors.
AID381847Inhibition of Escherichia coli DNA gyrase supercoiling activity2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis, structure and antibacterial activity of novel 1-(5-substituted-3-substituted-4,5-dihydropyrazol-1-yl)ethanone oxime ester derivatives.
AID1264555Antibacterial activity against methicillin-resistant Staphylococcus aureus 1118 for 18 to 20 hrs by broth microdilution method2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID765331Cell cycle arrest in human SKBR3 cells assessed as accumulation at subG1 phase at 1000 uM after 48 hrs by flow cytometric analysis (Rvb = 7 +/- 1%)2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
AID206171Tested for in vitro antibacterial activity against Staphylococcus aureus 011 HT3 phenotype2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID461176Inhibition of Escherichia coli DNA gyrase B ATPase activity2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
In silico discovery of 2-amino-4-(2,4-dihydroxyphenyl)thiazoles as novel inhibitors of DNA gyrase B.
AID219750Minimum inhibitory concentration against Xanthomonas maltophilia AC7392004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID465593Antibacterial activity against Escherichia coli K-12 W3110 after 20 hrs by liquid microdilution method2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Structure-activity relationships of bacterial outer-membrane permeabilizers based on polymyxin B heptapeptides.
AID571931Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-S623N mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID1449716Inhibition of Escherichia coli DNA topoisomerase 4 decatenation activity using kinetoplast DNA as substrate after 60 mins by ethidium bromide staining based agarose gel electrophoresis2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Indenocinnoline derivatives as G-quadruplex binders, topoisomerase IIα inhibitors and antiproliferative agents.
AID1558331Cytotoxicity against human HuH7 cells by MTT assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1580090Antibacterial activity against novobiocin-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages by checkerboard assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1867040Antimicrobial activity against Staphylococcus aureus JE2 ssessed as reduction in bacterial growth and measured for 24 hrs by resazurin dye based broth microdilution method
AID53458In vitro inhibition of supercoiling activity of Escherichia coli DNA gyrase subunit B compared to novabiocin.1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Synthesis and biological evaluation of coumarincarboxylic acids as inhibitors of gyrase B. L-rhamnose as an effective substitute for L-noviose.
AID396035Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID603459Antibacterial activity against Escherichia coli K-12 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID524262Antibacterial activity against Escherichia coli NKE155 harboring deletion mutation in acrB protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1671920Inhibition of Staphylococcus aureus DNA topoisomerase 4 using biotinylated oligonucleotide as substrate incubated for 30 mins in presence of ATP by fluorescence-based microplate reader assay2019European journal of medicinal chemistry, Apr-01, Volume: 167An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
AID1193923Cytotoxicity against mouse RAW264.7 cells at 100 uM after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
AID530051Antimicrobial activity against Staphylococcus aureus 286607-R1 harboring wild type gyrB by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
AID1337484Inhibition of human DNA topoisomerase-2alpha ATPase activity at 400 uM using supercoiled pBR322 DNA as substrate after 1 hr by malachite green dye based assay relative to control2017European journal of medicinal chemistry, Jan-05, Volume: 125Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors.
AID279370Antibacterial activity against Haemophilus influenzae ATCC 51907 after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID717082Antibacterial activity against Enterococcus faecalis CL85162012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1157275Antibacterial activity against Escherichia coli 5746 by resazurin-based assay2014Journal of natural products, May-23, Volume: 77, Issue:5
Mahorones, highly brominated cyclopentenones from the red alga Asparagopsis taxiformis.
AID510750Antibacterial activity against Escherichia coli AG102MB harboring pS1328-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID67571Inhibitory activity against Enterococcus faecalis KU 17772004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity.
AID529509Antibacterial activity against Escherichia coli DC2 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID673393Antibacterial activity against Streptococcus pneumoniae ARC5482012Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15
Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.
AID1303168Inhibition of Staphylococcus aureus DNA gyrase assessed as supercoiling of relaxed pNO1 plasmid after 30 mins by SybrGOLD staining based fluorescence assay2016European journal of medicinal chemistry, Jul-19, Volume: 117New N-phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATPase inhibitors of DNA gyrase.
AID544982Antimicrobial activity against Klebsiella pneumoniae 52OmpA2 at 80 ug/disk by disk diffusion method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Klebsiella pneumoniae OmpA confers resistance to antimicrobial peptides.
AID1399858Antitubercular activity against rifampicin-resistant Mycobacterium tuberculosis H37Rv harboring RpoB S522L mutant2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID524394Antibacterial activity against Escherichia coli NKE1355 harboring deletion mutation in acrB protein and plasmid expressing BAD gene in presence of increasing concentration of arabinose2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1226713Antimicrobial activity against Escherichia coli BW25113 expressing delta-tolC gene incubated for 16 to 18 hrs by macrodilution method2015ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4
Membrane-Targeting DCAP Analogues with Broad-Spectrum Antibiotic Activity against Pathogenic Bacteria.
AID591650Antimicrobial activity against Staphylococcus aureus Smith infected in iv dosed septicaemia Swiss albino mouse model after 4 days2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID1580083Antibacterial activity against wild type Acinetobacter baumannii ATCC 17978 assessed as resistant development at sub-MIC measured after 5 days of passaging by microbroth dilution method relative to control2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1278504Antibacterial activity against Pseudomonas aeruginosa at 30 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1520485Inhibition of Staphylococcus aureus DNA gyrase supercoiling activity using relaxed pHOT-1 DNA as substrate after 60 mins by ethidium bromide-based gel electrophoresis
AID530428Antimicrobial activity against Mycobacterium smegmatis overexpressing rv0194 gene by microplate Alamar blue assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis.
AID554402Antimicrobial activity against Pseudomonas aeruginosa isolate 3066 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID557114Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 180 to 250 ug/ml by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID381846Inhibition of Staphylococcus aureus DNA gyrase supercoiling activity2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis, structure and antibacterial activity of novel 1-(5-substituted-3-substituted-4,5-dihydropyrazol-1-yl)ethanone oxime ester derivatives.
AID433580Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as formation of DNA cleavable complex2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID606877Inhibition of Cdc37 interaction with [35S]His-tagged HRI K199R mutant in reticulocyte lysate assessed as coadsorbed Cdc37 at 4 mM after 40 mins by SDS-PAGE and Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1233813Inhibition of Staphylococcus aureus DNA topoisomerase 4 using kinetoplast DNA as substrate by decatenation assay2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.
AID1054854Inhibition of Mycobacterium tuberculosis DNA gyrase super coiling activity of relaxed pBR322 using ethidium bromide staining by agarose gel electrophoresis2013European journal of medicinal chemistry, , Volume: 70Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
AID23271Partition coefficient (logD7.4)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1054862Inhibition of Mycobacterium smegmatis GyrB ATPase activity expressed in Escherichia coli BL21 (DE3) at 50 uM after 2 hrs2013European journal of medicinal chemistry, , Volume: 70Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
AID1580091Antibacterial activity against colistin-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages by checkerboard assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID251761Percent inhibition of filarial parasite Setaria cervi by compound at 10 ug/mL concentration2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Syntheses of 2,4,6-trisubstituted pyrimidine derivatives as a new class of antifilarial topoisomerase II inhibitors.
AID1399854Inhibition of Mycobacterium tuberculosis DNA gyrase ATPase activity2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID279367Antibacterial activity against Enterococcus faecalis ATCC 29212 with GyrB T167I mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID205815Compound was tested in vitro for antibacterial activity against Staphylococcus aureus ATCC 259232000Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8
Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors.
AID1233794Inhibition of Escherichia coli DNA gyrase using relaxed pNO1 plasmid and biotinylated oligonucelotide incubated for 30 mins by fluorescence based DNA super-coiling assay2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1264560Antibacterial activity against Streptococcus pneumoniae 402 infected in sc dosed mouse assessed as reduction in 2 log CFU in lung compound administered as BID for 1 day measured 24 hrs after last dose2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID1359999Inhibition of Staphylococcus aureus DNA gyrase B preincubated for 10 mins followed by ATP addition measured after 30 mins by purine nucleoside phosphorylase enzyme coupled spectrophotometric method2018European journal of medicinal chemistry, Jun-25, Volume: 154New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
AID531336Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID1497257Antibacterial activity against Pseudomonas aeruginosa MTCC 4242018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Drug efficacy of novel 3-O-methoxy-4-halo disubstituted 5,7-dimethoxy chromans; evaluated via DNA gyrase inhibition, bacterial cell wall lesion and antibacterial prospective.
AID279373Antibacterial activity against novobiocin-resistant Haemophilus influenzae ATCC 51907 with GyrB R140L mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID554417Antimicrobial activity against mexXY operon inactivated Pseudomonas aeruginosa isolate 2715 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID717067Antibacterial activity against ciprofloxacin-resistant Staphylococcus aureus MB 5785 (R34)2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1482551Inhibition of Haemophilus influenzae DNA gyrase subunit GyrA/GyrB supercoiling activity expressed in Escherichia coli BL21 (DE3) using relaxed pBR322 DNA as substrate after 1 hr mins by agarose gel electrophoresis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID1775852Binding affinity to human GABARAPL1 expressed in Escherichia coli T7 by single site binding model based isothermal titration calorimetry2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.
AID1335287Antimycobacterial activity against Mycobacterium tuberculosis incubated for 7 days by alamar blue assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
AID1415765Antibacterial activity against Escherichia coli JW5503 transfected with empty vector in absence of IPTG induction after 16 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID425961Antimicrobial activity against Staphylococcus aureus RN4220 harboring tetracycline-regulable expression vector pAJ96 expressing Staphylococcus saprophyticus GyrB G85D, K140R mutant gene after 24 hrs by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Intrinsic novobiocin resistance in Staphylococcus saprophyticus.
AID564971Downregulation of p55 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID765334Cell cycle arrest in human SKBR3 cells assessed as accumulation at G2/M phase at 1000 uM after 48 hrs by flow cytometric analysis (Rvb = 21 +/- 1%)2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
AID1337486Inhibition of human DNA topoisomerase-2alpha ATPase activity at 200 uM using supercoiled pBR322 DNA as substrate after 1 hr by malachite green dye based assay relative to control2017European journal of medicinal chemistry, Jan-05, Volume: 125Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors.
AID1233793Inhibition of Escherichia coli DNA Gyrase ATPase activity assessed as reduction in conversion of NADH to NAD+ using linear pBR322 substrate2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.
AID560223Antibacterial activity against Salmonella enterica serovar Typhimurium R200 expressing Outer membrane protein STM3031 by CLSI M7-A7 agar dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID279363Antibacterial activity against Streptococcus pneumoniae ATCC BAA-255 with GyrB T172A and ParE T172A mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID1415734Antibacterial activity against gyramide-resistant Escherichia coli JW5503 harboring GyrA Ser97Pro mutant after 16 to 18 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID1775847Binding affinity to 15N-labelled human LC3B assessed as chemical shift perturbation at compound to protein molar ratio of 8:1 by NMR analysis2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.
AID308453Antibacterial activity against Staphylococcus aureus UC92182007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
Structure-activity relationships of bioisosteres of a carboxylic acid in a novel class of bacterial translation inhibitors.
AID530429Resistance factor, ratio of MIC for Mycobacterium smegmatis overexpressing rv0194 gene to MIC for wild-type Mycobacterium smegmatis SMR52008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis.
AID1652707Induction of Escherichia coli K12 MG1655 lexA promotor measured at 30 mins interval for 20 hrs by fluorescence assay relative to control
AID621296Antibacterial activity against Escherichia coli ATCC 25922 after 18 to 24 hrs by CLSI M100-S17 method2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Mannich reaction derivatives of novobiocin with modulated physiochemical properties and their antibacterial activities.
AID567644Displacement of novobiocin bound sepharose from HSP90 after 5 mins by affinity chromatography analysis2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID1482534Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID765344Inhibition of HSP90 in rabbit reticulocyte lysate assessed as inhibition of heat-denatured luciferase refolding at 500 uM by luminescence plate reader analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
AID456227Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS/PMS assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone.
AID534106Antibacterial activity against Pasteurella multocida AL435 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID369261Effect on ompF-lacZ fusion transcription in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID396041Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pBGS18 plasmid by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID308989Antibacterial activity against Staphylococcus aureus ATCC 25923 by twofold agar dilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors.
AID53455Maximal noneffective concentration for inhibition of DNA gyrase using supercoiling assay.2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.
AID1303166Inhibition of Escherichia coli DNA gyrase assessed as supercoiling of relaxed pNO1 plasmid after 30 mins by SybrGOLD staining based fluorescence assay2016European journal of medicinal chemistry, Jul-19, Volume: 117New N-phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATPase inhibitors of DNA gyrase.
AID425953Antimicrobial activity against Staphylococcus aureus SH1000 after 24 hrs by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Intrinsic novobiocin resistance in Staphylococcus saprophyticus.
AID446852Inhibition of Streptococcus pneumoniae SP-3 gyrB by enzyme coupled phosphate assay2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV.
AID209780Tested for in vitro antibacterial activity against Streptococcus pyogenes O2A1UC1 phenotype2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID529162FIC index, ratio of MIC for Pseudomonas aeruginosa 25619 in presence of 250 ug/ml polyethylenimine to MIC for Pseudomonas aeruginosa 256192008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID68223Antibacterial activity against vancomycin, teicoplanin and erythromycin resistant Enterococcus faecium 02D31P2 strain1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B.
AID427450Inhibition of Bacillus subtilis DNA gyrase by gel mobility assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Discovery, characterization and comparison of inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicases.
AID206819Minimum inhibitory concentration against Staphylococcus pyogenes b152004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID425963Ratio of MIC for Staphylococcus aureus RN4220 harboring tetracycline-regulable expression vector pAJ96 expressing Staphylococcus saprophyticus GyrB gene to MIC for Staphylococcus aureus RN42202007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Intrinsic novobiocin resistance in Staphylococcus saprophyticus.
AID575170Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID283560Antibacterial activity against Escherichia coli HNCE4 after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID67570Inhibitory activity against Enterococcus faecalis ATCC 292122004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity.
AID425960Antimicrobial activity against Staphylococcus aureus RN4220 harboring tetracycline-regulable expression vector pAJ96 expressing Staphylococcus saprophyticus GyrB K140R mutant gene after 24 hrs by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Intrinsic novobiocin resistance in Staphylococcus saprophyticus.
AID279375Antibacterial activity against Staphylococcus aureus ATCC 29213 carrying plasmid expressing wild type GyrB2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID1323397Inhibition of Escherichia coli DNA topoisomerase 4 assessed as reduction in decatenation of supercoiled pNO1 DNA after 30 mins in presence of biotinylated oligonucleotide by sybrGOLD staining based fluorescence assay2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.
AID53318Inhibitory activity against Escherichia coli DNA gyrase2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity.
AID206133In vitro antibacterial activity against Staphylococcus aureus 011GO76 OfloOxaEry-R1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B.
AID308995Antibacterial activity against Streptococcus pyogenes beta-15 by agar dilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors.
AID1054861Inhibition of Mycobacterium smegmatis GyrB ATPase activity expressed in Escherichia coli BL21 (DE3) at 25 uM after 2 hrs2013European journal of medicinal chemistry, , Volume: 70Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
AID205818Compound was tested in vitro for antibacterial activity against Staphylococcus aureus NovoR2000Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8
Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors.
AID1415766Antibacterial activity against Escherichia coli JW5503 overexpressing gyrA in presence of IPTG induction after 16 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID603364Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID325448Antibacterial activity against Staphylococcus aureus Mu50 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID557096Binding affinity to human alpha-1-acid glycoprotein assessed as compound binding sites level by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1127623Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae D39 NCTC 7466 expressing GyrA S81F/ParC S79Y double mutant assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID554427Ratio of MIC for mexB deficient Pseudomonas aeruginosa FB1 mutant to Pseudomonas aeruginosa PAO12009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID524385Antibacterial activity against Escherichia coli NKE156 harboring deletion mutation in acrB protein and vector expressing acrD gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1130041Inhibition of Escherichia coli DNA gyrase-mediated supercoiling of relaxed DNA using N0471S as substrate after 30 mins by using ethidium iodide staining-based agarose gel electrophoresis2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Computer-aided identification of novel 3,5-substituted rhodanine derivatives with activity against Staphylococcus aureus DNA gyrase.
AID1406901Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by agar dilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel coumarin-pyrazole carboxamide derivatives as potential topoisomerase II inhibitors: Design, synthesis and antibacterial activity.
AID1167978Antimicrobial activity against Staphylococcus aureus MTCC 3160 after 16 to 24 hrs by agar dilution method2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus.
AID1652709Induction of Escherichia coli K12 MG1655 sulA promotor measured at 30 mins interval for 20 hrs by fluorescence assay relative to control
AID571884Antibacterial activity against Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID396036Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID1415733Antibacterial activity against gyramide-resistant Escherichia coli JW5503 harboring GyrA Pro35Thr mutant after 16 to 18 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID340860Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 vraG mutant microdilution assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID392672Toxicity in retinoic acid-differentiated human SH-SY5Y cells assessed as effect on cell morphology at 10 uM after 24 hrs by trypan blue exclusion method2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line.
AID1226730Antimicrobial activity against Escherichia coli MG1655 incubated at 37 degC overnight for 18 hrs2015ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4
Membrane-Targeting DCAP Analogues with Broad-Spectrum Antibiotic Activity against Pathogenic Bacteria.
AID325447Antibacterial activity against Staphylococcus aureus N315 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID53317Iinhibitory activity against Escherichia coli DNA gyrase2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID532762Antimicrobial activity against Salmonella serovar Typhimurium SL1344 by broth dilution method in presence of chlorpromazine2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID1413262Binding affinity to His6-sumo-tagged Escherichia coli K-12 GyrB ATPase domain expressed in Escherichia coli BL21 (DE3) assessed as change in melting temperature at 1 mM by SYPRO orange dye-based RT-PCR method2018MedChemComm, Oct-01, Volume: 9, Issue:10
Identification of an auxiliary druggable pocket in the DNA gyrase ATPase domain using fragment probes.
AID369265Effect on ompF-lacZ fusion transcription in marA-negative Escherichia coli CH164 mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1278500Antibacterial activity against Proteus sp. at 30 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1482537Antibacterial activity against methicillin/fluoroquinolone-resistant Staphylococcus aureus A-798 harboring topoisomerase gyrA S84L mutant/grlA S80F/Glu84V mutant by broth microdilution method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID534110Antibacterial activity against TolC deficient Pasteurella multocida pm1980 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID554390Antimicrobial activity against Pseudomonas aeruginosa isolate 615S obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID529388Antibacterial activity against Staphylococcus aureus ATCC 43300 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID603363Antibacterial activity against vancomycin resistant Enterococcus NCTC 12201 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID557113Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 120 ug/ml by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1264565Clearance in mouse at 2 mg/kg, iv by LC-MS/MS analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID1482542Antibacterial activity against vancomycin/fluoroquinolone-resistant Enterococcus faecium A-949 harboring topoisomerase gyrA E88K mutant/parC S80R mutant by broth microdilution method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID1130046Inhibition of Staphylococcus aureus DNA gyrase subunit B ATPase activity assessed as consumption of inorganic phosphate by PNP-based absorbance assay2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Computer-aided identification of novel 3,5-substituted rhodanine derivatives with activity against Staphylococcus aureus DNA gyrase.
AID1323395Inhibition of Escherichia coli DNA gyrase B ATP binding site assessed as reduction in supercoiling of relaxed pNO1 DNA after 30 mins in presence of biotinylated oligonucleotide by sybrGOLD staining based fluorescence assay2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.
AID530065Inhibition of Escherichia coli DNA gyrase by gel electrophoresis2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
AID1608453Antiviral activity against Zika virus2019European journal of medicinal chemistry, Oct-15, Volume: 180Cell-active carbazole derivatives as inhibitors of the zika virus protease.
AID69620Antibacterial activity against Escherichia coli K 9012004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID1688282Inhibition of Staphylococcus aureus Gyrase B using linear pBR322 DNA as substrate incubated for 30 mins in presence of ATP by ADP-Glo assay2020European journal of medicinal chemistry, Feb-15, Volume: 188N-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: Design, synthesis, biological evaluation and target identification.
AID1326670Inhibition of Mycobacterium smegmatis 155 6His-tagged DNA gyrase B catalytic domain ATPase activity expressed in Escherichia coli BL21 (DE3) pLysS cells assessed as inorganic phosphate release after 120 mins in presence of ATP by malachite green dye based2016European journal of medicinal chemistry, Oct-21, Volume: 122Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
AID554394Antimicrobial activity against Pseudomonas aeruginosa isolate 2715 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1482530Inhibition of Escherichia coli N-terminal His6-tagged DNA gyrase subunit GyrA/GyrB supercoiling activity expressed in Escherichia coli BL21 (DE3) using relaxed pBR322 DNA as substrate after 1 hr by agarose gel electrophoresis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID765342Inhibition of HSP90 in rabbit reticulocyte lysate assessed as inhibition of heat-denatured luciferase refolding after 30 mins by luminescence plate reader analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
AID303880Cell cycle arrest in MCF7 cells assessed as accumulation at S phase at 200 uM after 72 hrs by flow cytometry2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
AID206876Antibacterial activity against Staphylococcus aureus FDA 209P2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID230600Range for minimum inhibitory concentration against Enterococcus faecalis;4-82004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID1852754Antibacterial activity against wild type Escherichia coli ATCC 25922 assessed as bacterial growth inhibition by broth microdilution assay2022RSC medicinal chemistry, Sep-21, Volume: 13, Issue:9
Design and evaluation of poly-nitrogenous adjuvants capable of potentiating antibiotics in Gram-negative bacteria.
AID275055Antibacterial activity against Escherichia coli pTMV192006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
AID1415767Antibacterial activity against Escherichia coli JW5503 overexpressing gyrA in absence of IPTG induction after 16 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID728673Antimicrobial activity against hldE-deficient Escherichia coli O18:K1:H7 after overnight incubation2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Novel HldE-K inhibitors leading to attenuated Gram negative bacterial virulence.
AID443313Inhibition of HSP902009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Evaluation of di-sansalvamide A derivatives: synthesis, structure-activity relationship, and mechanism of action.
AID1775858Binding affinity to human LC3B expressed in Escherichia coli BL21-(DE3) by isothermal titration calorimetry2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.
AID303878Cell cycle arrest in MCF7 cells assessed as accumulation at subG1 phase at 200 uM after 72 hrs by flow cytometry2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
AID209270Antibacterial activity tested against Streptococcus pyogenes 02AIUC12000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Coumarin inhibitors of gyrase B with N-propargyloxy-carbamate as an effective pyrrole bioisostere.
AID717078Antibacterial activity against Escherichia coli MB5746 expressing envA1, tolC2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1188156Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 100 uM after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
AID205580Compound was evaluated for antibacterial activity, against oxacillin and teicoplanin resistant Staphylococcus epidermidis 012GO39 strain1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B.
AID520089Inhibition of reconstituted Xanthomonas albilineans DNA gyrase subunit AB assessed as reduction of DNA supercoiling activity using pBR322 DNA substrate2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
DNA gyrase from the albicidin producer Xanthomonas albilineans has multiple-antibiotic-resistance and unusual enzymatic properties.
AID567637Inhibition of human HSP90alpha expressed in yeast PP30 cells co-expressing HSF-lacZ reporter assessed as inhibition of heat stress-induced response at 100 uM after 3 hrs2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID633097Cytotoxicity against human Jurkat T-lymphoblastoid leukemia cells after 24 to 48 hrs by MTS assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
A small molecule that preferentially binds the closed conformation of Hsp90.
AID1186427Antimicrobial activity against Staphylococcus aureus ATCC 19636 infected in neutropenic mouse assessed as reduction in colony forming units at 30 mg/kg, iv administered as single dose measured 24 hrs post infection relative to control2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Discovery and in vivo evaluation of alcohol-containing benzothiazoles as potent dual-targeting bacterial DNA supercoiling inhibitors.
AID529395Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID584326Antibacterial activity against tolC deficient Escherichia coli GD1002010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID1181925Inhibition of HSP90 in rabbit reticulocyte lysate after 90 mins by luciferase renaturation assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.
AID567626Inhibition of HSP90 binding to Cdc37 in human SKBR-3 cells 10 uM by Western blotting2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID369263Effect on ompF-lacZ fusion transcription in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID308994Antibacterial activity against Staphylococcus epidermidis ATCC 14990 by twofold agar dilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors.
AID524387Antibacterial activity against Escherichia coli NKE1365 harboring deletion mutation in acrB and mdtABC protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID479089Growth inhibition in Streptomyces 85E assessed as clear zone of inhibition at 10 ug/disk by hyphae formation inhibition assay2010Journal of natural products, May-28, Volume: 73, Issue:5
Coumabiocins A-F, aminocoumarins from an organic extract of Streptomyces sp. L-4-4.
AID529512Antibacterial activity against Pseudomonas aeruginosa K799/WT by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID1459324Inhibition of Escherichia coli DNA gyrase using relaxed pBR322 DNA as substrate after 3 hrs by agarose electrophoresis2017European journal of medicinal chemistry, Jan-05, Volume: 125Linker-switch approach towards new ATP binding site inhibitors of DNA gyrase B.
AID554398Antimicrobial activity against Pseudomonas aeruginosa isolate 2804 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID498880Antimicrobial activity against Escherichia cloi RAM1129 transfected with pNK1 containg Neisseria meningitidis tolC gene by agar dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Biologic activities of the TolC-like protein of Neisseria meningitidis as assessed by functional complementation in Escherichia coli.
AID1482545Inhibition of fluoroquinolone-resistant Staphylococcus aureus clinical isolate DNA gyrase subunit GyrB/GyrA S84L mutant supercoiling activity using relaxed pBR322 DNA as substrate after 1 hr by agarose gel electrophoresis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID1323396Inhibition of Staphylococcus aureus DNA gyrase B ATP binding site assessed as reduction in supercoiling of relaxed pNO1 DNA after 30 mins in presence of biotinylated oligonucleotide by sybrGOLD staining based fluorescence assay2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.
AID584330Antibacterial activity against ygiBC, yjfMC, gspS deficient Escherichia coli GD1082010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID606954Effect on [35S]His-tagged HRI stability in heme-deficient reticulocyte lysate assessed as loss of [35S]His-tagged HRI at 4 mM after 45 mins by SDS-PAGE and autoradiography2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID572058Ratio of MIC for Escherichia coli KAM32 harboring plasmid pUC18 to MIC for Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID1127615Antibacterial activity against wild type Streptococcus pneumoniae assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID557111Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 7 to 15 ug/ml by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID530066Inhibition of Escherichia coli DNA topoisomerase 4 by gel electrophoresis2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
AID451988Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
AID446853Inhibition of Streptococcus pneumoniae SP-3 parE after 30 mins2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV.
AID1604455Antiproliferative activity against human MCF7 cells2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
AID1415772Antibacterial activity against Escherichia coli JW5503 overexpressing gyrB at 51 ug/ml in presence of IPTG induction after 16 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID205600Compound was tested in vitro for antibacterial activity against Staphylococcus epidermidis ATCC 149902000Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8
Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors.
AID1233796Inhibition of Staphylococcus aureus DNA gyrase using relaxed pNO1 plasmid and biotinylated oligonucelotide incubated for 30 mins by fluorescence based DNA super-coiling assay2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.
AID554424Antimicrobial activity against mexXY operon inactivated Pseudomonas aeruginosa isolate 2998 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID369259Effect on ompF-lacZ fusion transcription in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1127633Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae D39 NCTC 7466 expressing GyrB/ParE T172A mutant assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method wild type Streptococcus pneumoniae2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID68237In vitro antibacterial activity against Enterococcus faecium 02D31P2 VanTeiEry-R strain1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Synthesis and biological evaluation of coumarincarboxylic acids as inhibitors of gyrase B. L-rhamnose as an effective substitute for L-noviose.
AID554389Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY F1018L mutant by twofold macrodilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID381843Antibacterial activity against Pseudomonas fluorescens ATCC 135252008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis, structure and antibacterial activity of novel 1-(5-substituted-3-substituted-4,5-dihydropyrazol-1-yl)ethanone oxime ester derivatives.
AID524384Antibacterial activity against Escherichia coli NKE126 harboring deletion mutation in acrB and acrD protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID567627Inhibition of HSP90 in human MCF7 cells assessed as degradation of Hsp70 protein up to 50 uM after 48 hrs by Western blotting2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID1280924Cytotoxicity against human SKBR3 cells by MTS assay2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Novobiocin Analogues That Inhibit the MAPK Pathway.
AID673392Antibacterial activity against methicillin-sensitive Staphylococcus aureus2012Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15
Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.
AID1053270Inhibition of ACE (unknown origin) assessed as 3-Hydroxybutyril-glycil-glycil-glycine conversion to 3-hydroxybutyric acid after 60 mins by WST assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID572061Ratio of MIC for Acinetobacter baumannii AC0037 to MIC for abeS-deficient Acinetobacter baumannii AC00372009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID1579940Bacteriostatic activity against Klebsiella pneumoniae 116381 at 50.4 uM in LB media after 24 hrs by time-kill assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID367054Antibacterial activity against efflux pump mutant expressing Escherichia coli ATCC N432009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.
AID554388Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY F29S mutant by twofold macrodilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1303170Inhibition of Escherichia coli topoisomerase 4 assessed as supercoiling of relaxed pNO1 plasmid after 30 mins by SybrGOLD staining based fluorescence assay2016European journal of medicinal chemistry, Jul-19, Volume: 117New N-phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATPase inhibitors of DNA gyrase.
AID510748Antibacterial activity against Escherichia coli AG102MB harboring naive acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID591657Antimicrobial activity against Streptococcus pyogenes b15 after 18 hrs by agar dilution method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.
AID1399856Antitubercular activity against fluoroquinolone-resistant Mycobacterium tuberculosis H37Rv harboring gyrA D94N mutant2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID303874Cell cycle arrest in MCF7 cells assessed as accumulation at subG1 phase at 200 uM after 48 hrs by flow cytometry2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1264563Volume of distribution at steady state in mouse at 2 mg/kg, iv by LC-MS/MS analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID501418Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315 after 24 hrs by microdilution assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.
AID1482544Antibacterial activity against Haemophilus influenzae A-921 by broth microdilution method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID1264551Antibacterial activity against Staphylococcus aureus 1118 infected in sc and iv dosed mouse assessed as septicemia compound administered 1 hr post-infection twice for 1 day measured for 7 days2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID369615Effect on ompF-lacZ fusion translation in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1252464Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 50 uM incubated for 48 hrs at 37 degC by MTT assay relative to control2015European journal of medicinal chemistry, Oct-20, Volume: 1034-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
AID1415740Antibacterial activity against ciprofloxacin-resistant Escherichia coli JW5503 harboring GyrA Asp87Tyr mutant after 16 to 18 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID1127617Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae D39 NCTC 7466 expressing ParE/GyrB K143I mutant assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID477409Antibacterial activity against Staphylococcus aureus NCTC 8325 after 16 to 20 hrs by broth microdilution method2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.
AID369251Increase in ompX-lacZ expression in Escherichia coli JM109 assessed as increase in beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1415764Antibacterial activity against Escherichia coli JW5503 transfected with empty vector in presence of IPTG induction after 16 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID606948Inhibition of Hsp90-mediated [35S]His-tagged HRI maturation in heme-deficient reticulocyte lysate at 4 mM after 45 mins by SDS-PAGE and autoradiography2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1399842Antibacterial activity against Mycobacterium tuberculosis H37Rv measured after 5 days by resazurin-dye based microplate assay2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID251763Percent inhibition of filarial parasite Setaria cervi by compound at 40 ug/mL concentration2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Syntheses of 2,4,6-trisubstituted pyrimidine derivatives as a new class of antifilarial topoisomerase II inhibitors.
AID534112Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm19802008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1688284Inhibition of Staphylococcus aures ParE using pBR322 DNA as substrate in presence of ATP2020European journal of medicinal chemistry, Feb-15, Volume: 188N-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: Design, synthesis, biological evaluation and target identification.
AID425958Antimicrobial activity against Staphylococcus aureus RN4220 harboring tetracycline-regulable expression vector pAJ96 expressing Staphylococcus saprophyticus GyrB gene after 24 hrs by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Intrinsic novobiocin resistance in Staphylococcus saprophyticus.
AID673391Antibacterial activity against methicillin-, quinolone-resistant Staphylococcus aureus2012Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15
Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.
AID1233798Inhibition of Escherichia coli DNA topoisomerase 4 using relaxed pNO1 plasmid and biotinylated oligonucelotide incubated for 30 mins by fluorescence based DNA relaxation assay2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.
AID1652706Induction of Escherichia coli K12 MG1655 recA promotor measured at 30 mins interval for 20 hrs by fluorescence assay relative to control
AID1053271Inhibition of ACE (unknown origin) assessed as 3-Hydroxybutyril-glycil-glycil-glycine conversion to 3-hydroxybutyric acid at 500 uM after 60 mins by WST assay relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID567640Antiproliferative activity against human LNCaP-LN3 cells2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID1278505Antibacterial activity against Staphylococcus aureus at 30 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID325445Antibacterial activity against Escherichia coli C921-61 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID567630Modulation proteolytic fingerprint of HSP90 in rabbit reticulocyte lysates at 20 mM after 5 mins by SDS-PAGE analysis in presence of 125 ug/ml of trypsin2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID425962Ratio of MIC for Staphylococcus aureus RN4220 harboring tetracycline-regulable expression vector pAJ96 expressing Staphylococcus saprophyticus GyrB gene to MIC for Staphylococcus aureus SH10002007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Intrinsic novobiocin resistance in Staphylococcus saprophyticus.
AID451987Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
AID56393Iinhibitory activity against Escherichia coli DNA topoisomerase IV2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID1482548Inhibition of Streptococcus pneumoniae DNA gyrase subunit GyrA/GyrB supercoiling activity expressed in Escherichia coli BL21 (DE3) using relaxed pBR322 DNA as substrate after 1 hr mins by agarose gel electrophoresis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID1415736Antibacterial activity against gyramide-resistant Escherichia coli JW5503 harboring GyrA His45Tyr mutant after 16 to 18 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID1580059Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 615892019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID364886Inhibition of P-gp in human adriamycin-resistant A2780 cells up to 300 uM by Hoechst 33342 assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
AID717076Inhibition of Escherichia coli DNA gyrase2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1497259Antibacterial activity against Corynebacterium diphtheriae MTCC 1162018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Drug efficacy of novel 3-O-methoxy-4-halo disubstituted 5,7-dimethoxy chromans; evaluated via DNA gyrase inhibition, bacterial cell wall lesion and antibacterial prospective.
AID660261Ratio of MIC for wild type Escherichia coli JC7623 to MIC for acrAB-deficient Escherichia coli JZM1202012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID279364Antibacterial activity against Enterococcus faecalis ATCC 29212 after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID1415712Antibacterial activity against Escherichia coli JW5503 after 16 to 18 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID1180375Antiproliferative activity against human SKBR3 cells2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines.
AID529390Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID1156899Growth inhibition of ER-positive human MCF7 cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1406902Antibacterial activity against Salmonella enterica ATCC 9184 after 24 hrs by agar dilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel coumarin-pyrazole carboxamide derivatives as potential topoisomerase II inhibitors: Design, synthesis and antibacterial activity.
AID717075Inhibition of Escherichia coli topoisomerase-42012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1252463Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition incubated for 7 days by microplate alamar blue assay2015European journal of medicinal chemistry, Oct-20, Volume: 1034-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
AID603461Inhibition of Escherichia coli DNA gyrase assessed as inhibition of pBR322 supercoiling by densitometry2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID53327In vitro maximum non-effective concentration against Escherichia coli DNA gyrase supercoiling activity.2000Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8
Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors.
AID603367Antibacterial activity against methicillin-resistant Staphylococcus aureus N315 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID680983TP_TRANSPORTER: inhibition of glyburide accumulation by novobiocin at a concentration of 200uM in BCRP-expressing MCF7-MX cells
AID1446681Inhibition of Staphylococcus aureus topoisomerase 4 ParE supercoiling activity using relaxed pNO1 DNA as substrate after 30 mins in presence of biotin-labeled oligonucleotide by SybrGOLD staining based fluorescence assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
AID717086Antibacterial activity against methicillin-sensitive Staphylococcus aureus MB 28652012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID765361Cell cycle arrest in human SKBR3 cells assessed as accumulation at G0/G1 phase at 1000 uM after 48 hrs by flow cytometric analysis (Rvb = 54 +/- 2%)2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
AID1181926Inhibition of HSP90 in human MDA-kb2 cells assessed as reduction in glucocorticoid receptor-dependent luciferase expression after 18 hrs by firefly luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.
AID1580058Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 335922019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1497258Antibacterial activity against Staphylococcus aureus MTCC 962018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Drug efficacy of novel 3-O-methoxy-4-halo disubstituted 5,7-dimethoxy chromans; evaluated via DNA gyrase inhibition, bacterial cell wall lesion and antibacterial prospective.
AID571768Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-I626M mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID1127580Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae D39 NCTC 7466 expressing GyrB K143A/ParE T172A double mutant assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method wild type Streptococcus pneu2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID205896Minimum inhibitory concentration against Staphylococcus epidermidis 16/22004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID1666221Inhibition of HSP90 at C-terminus (unknown origin)2020ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8
From Bacteria to Cancer: A Benzothiazole-Based DNA Gyrase B Inhibitor Redesigned for Hsp90 C-Terminal Inhibition.
AID489699Antiproliferative activity against human MCF7 cells expressing ER2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues.
AID279355Antibacterial activity against Staphylococcus aureus ATCC 29213 with GyrB T173I mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID279358Antibacterial activity against Staphylococcus aureus ATCC 29213 with GyrB T173I and GrlB T166A mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID479093Growth inhibition in Streptomyces 85E assessed as clear zone of inhibition at 5 ug/disk by hyphae formation inhibition assay2010Journal of natural products, May-28, Volume: 73, Issue:5
Coumabiocins A-F, aminocoumarins from an organic extract of Streptomyces sp. L-4-4.
AID498877Antimicrobial activity against Escherichia coli RAM4100 by agar dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Biologic activities of the TolC-like protein of Neisseria meningitidis as assessed by functional complementation in Escherichia coli.
AID1399848Antibacterial activity against Haemophilus influenzae ATCC 49247 by agar dilution method2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID1113099Antibacterial activity against Bacillus subtilis after 24 hr by microdilution method2013Journal of agricultural and food chemistry, Mar-27, Volume: 61, Issue:12
Isolation and characterization of new p-Terphenyls with antifungal, antibacterial, and antioxidant activities from halophilic actinomycete Nocardiopsis gilva YIM 90087.
AID446854Antibacterial activity against Staphylococcus aureus UC76 by NCCLS method2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV.
AID603475Antibacterial activity against methicillin-susceptible Staphylococcus aureus 209P after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID554425Antimicrobial activity against mexXY operon inactivated Pseudomonas aeruginosa isolate 3066 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1167981Cytotoxicity against human HEK293 cells assessed as reduction in cell viability at 100 uM after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus.
AID367052Antibacterial activity against Staphylococcus aureus ATCC 292132009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1194334Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 incubated for 7 days by microplate alamar blue assay method2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
AID283558Antibacterial activity against Escherichia coli AG102 with marR1 mutation after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID537736Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1446687Inhibition of Escherichia coli DNA gyrase supercoiling activity using relaxed pBR322 DNA as substrate after 45 mins by ethidium-bromide staining based agarose gel electrophoresis2017European journal of medicinal chemistry, Apr-21, Volume: 130Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
AID279369Antibacterial activity against Enterococcus faecalis ATCC 29212 with GyrB T167A and ParE T169A mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID279380Antibacterial activity against Staphylococcus aureus ATCC 29213 with GyrB T173N mutation without plasmid2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID1188154Inhibition of Mycobacterium tuberculosis DNA gyrase supercoiling activity using relaxed pBR322 substrate incubated for 30 mins by ethidium bromide staining method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
AID721531Antiproliferative activity against human SKBR3 cells2013Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2
Novobiocin analogues with second-generation noviose surrogates.
AID367053Antibacterial activity against Enterococcus faecalis ATCC 292122009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.
AID1447478Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by microtiter dilution assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID279356Antibacterial activity against novobiocin-resistant Staphylococcus aureus ATCC 29213 with GyrB R144I mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID1278503Antibacterial activity against Escherichia coli at 30 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID717073Inhibition of Staphylococcus aureus topoisomerase-42012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID529391Antibacterial activity against Streptococcus pneumoniae SL336-T by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID557090Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 0.1% alpha-1-acid glycoprotein2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID534109Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm05272008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID501422Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 24 hrs by microdilution assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.
AID433400Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as DNA supercoiling inhibition2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID1482527Inhibition of Staphylococcus aureus N-terminal His6-tagged DNA gyrase subunit GyrA/GyrB supercoiling activity expressed in Escherichia coli BL21 (DE3) using relaxed pBR322 DNA as substrate after 1 hr by agarose gel electrophoresis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID308990Antibacterial activity against novobiocin R144I-resistant Staphylococcus aureus ATCC 25923 by agar dilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors.
AID1652708Induction of Escherichia coli K12 MG1655 recN promotor measured at 30 mins interval for 20 hrs by fluorescence assay relative to control
AID654691Inhibition of DNA gyrase B2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
In silico discovery and biophysical evaluation of novel 5-(2-hydroxybenzylidene) rhodanine inhibitors of DNA gyrase B.
AID554414Antimicrobial activity against mexXY operon inactivated Pseudomonas aeruginosa isolate 615R obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID567636Inhibition of HSP90 in human MCF7 cells assessed as degradation of Her2 protein after 48 hrs by Western blotting2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID1113091Antioxidant activity assessed as superoxide anion radical scavenging activity at 2 mg/ml after 5 min by spectrophotometric analysis2013Journal of agricultural and food chemistry, Mar-27, Volume: 61, Issue:12
Isolation and characterization of new p-Terphenyls with antifungal, antibacterial, and antioxidant activities from halophilic actinomycete Nocardiopsis gilva YIM 90087.
AID524261Antibacterial activity against Escherichia coli NKE154 harboring vector expressing acrB deletion mutant2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID584329Antibacterial activity against gspS deficient Escherichia coli JW2956-12010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID1659175Inhibition of Zika virus NS2B-NS3 protease2020Bioorganic & medicinal chemistry letters, 03-01, Volume: 30, Issue:5
Inhibitors of the Zika virus protease NS2B-NS3.
AID1167980Inhibition of biofilm formation in methicillin-resistant Staphylococcus aureus MTCC 96 after 36 hr incubation by tissue culture plate method2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus.
AID510749Antibacterial activity against Escherichia coli AG102MB harboring pP10-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID1446677Inhibition of Staphylococcus aureus DNA gyrase A/DNA gyrase B supercoiling activity using relaxed pNO1 DNA as substrate after 30 mins in presence of biotin-labeled oligonucleotide by SybrGOLD staining based fluorescence assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
AID1399838Antibacterial activity against Escherichia coli ATCC 259222018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID660262Ratio of MIC for wild type Escherichia coli TG1 to MIC for acrB-deficient Escherichia coli KAM3 by two-fold serial dilution method2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID567639Antiproliferative activity against human LNCAP cells2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID1272963Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by alamar blue assay2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.
AID1756501Inhibition of Escherichia coli topoisomerase assessed as reduction in relaxation of supercoiled pNO1 DNA measured after 30 mins by fluorescence assay2021European journal of medicinal chemistry, Mar-05, Volume: 213New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.
AID534111Antibacterial activity against Pasteurella multocida pm1980 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1167977Inhibition of Staphylococcus aureus DNA gyrase-mediated supercoiling of relaxed DNA using pBR 322 as substrate by agarose gel electrophoresis analysis2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus.
AID554418Antimicrobial activity against mexXY operon inactivated Pseudomonas aeruginosa isolate 2716 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID279368Antibacterial activity against Enterococcus faecalis ATCC 29212 with GyrB T167I and ParE T169A mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID279361Antibacterial activity against Streptococcus pneumoniae ATCC BAA-255 with ParE T172A mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID1461756Inhibition of human DNA topoisomerase 2 ATPase activity at 200 mM by Topo-2 ATPase assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Recent synthetic and medicinal perspectives of tryptanthrin.
AID1506346Inhibition of full length chicken Hsp90beta (1 to 728 amino acids)2017MedChemComm, Mar-01, Volume: 8, Issue:3
A Scaffold Merging Approach to Hsp90 C-terminal Inhibition: Synthesis and Evaluation of a Chimeric Library.
AID68566Tested for in vitro antibacterial activity against Enterococcus faecium 02D31P2 vancomycin teicoplanin erythromycin resistance phenotype2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID1461757Inhibition of human DNA topoisomerase 2 ATPase activity at 400 mM by Topo-2 ATPase assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Recent synthetic and medicinal perspectives of tryptanthrin.
AID367051Inhibition of Escherichia coli DNA topoisomerase 4 subunit B ParE assessed as inorganic phosphate release by malachite green complex formation assay2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.
AID1482531Inhibition of Escherichia coli DNA topoisomerase 4 subunit ParC/ParE relaxation expressed in Escherichia coli BL21 (DE3) using supercoiled pBR322 DNA as substrate after 1 hr by agarose gel electrophoresis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID279362Antibacterial activity against Streptococcus pneumoniae ATCC BAA-255 with ParE T172I mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID1415768Antibacterial activity against Escherichia coli JW5503 overexpressing gyrB in presence of IPTG induction after 16 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID534107Antibacterial activity against TolC deficient Pasteurella multocida pm0527 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID567625Inhibition of HSP90 binding to Cdc37 in human SKBR-3 cells 1 mM by Western blotting2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID529394Antibacterial activity against Enterococcus faecium ATCC 19434 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1671924Inhibition of Staphylococcus aureus DNA gyrase using biotinylated oligonucleotide as substrate incubated for 30 mins in presence of ATP by fluorescence-based microplate reader assay2019European journal of medicinal chemistry, Apr-01, Volume: 167An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
AID206814In vitro antibacterial activity against Streptococcus pyogenes O2A1UC1 strain1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Synthesis and biological evaluation of coumarincarboxylic acids as inhibitors of gyrase B. L-rhamnose as an effective substitute for L-noviose.
AID1775854Displacement of sGFP-p62-LIR peptide from human N-terminal SNAP-fused LC3A by time-resolved FRET assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.
AID557112Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 60 ug/ml by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1558329Inhibition of NS2B-NS3 protease in Zika virus Puerto Rico/PRVABC5 assessed as antiviral activity measured 48 hrs post infection by plaque reduction assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID369266Effect on ompF-lacZ fusion transcription in marA-negative Escherichia coli CH164 mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1130034Antimicrobial activity against Staphylococcus aureus carolina after 24 hrs by two-fold serial dilution method2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Computer-aided identification of novel 3,5-substituted rhodanine derivatives with activity against Staphylococcus aureus DNA gyrase.
AID1065133Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS assay2014ACS medicinal chemistry letters, Jan-09, Volume: 5, Issue:1
Identification of a new scaffold for hsp90 C-terminal inhibition.
AID1127619Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae D39 NCTC 7466 expressing GyrB T172A/ParE T172A double mutant assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID446860Antibacterial activity against Streptococcus pyogenes C203 by NCCLS method2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV.
AID679622TP_TRANSPORTER: inhibition of mitoxantrone efflux in BCRP-expressing MCF7-MX cells
AID1335286Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 100 uM measured after 72 hrs by MTT assay relative to control2016European journal of medicinal chemistry, Nov-29, Volume: 124Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
AID1852760Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 assessed as bacterial growth inhibition by broth microdilution assay2022RSC medicinal chemistry, Sep-21, Volume: 13, Issue:9
Design and evaluation of poly-nitrogenous adjuvants capable of potentiating antibiotics in Gram-negative bacteria.
AID1399841Antibacterial activity against Enterococcus faecalis ATCC 29212 by agar dilution method2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID1130037Antimicrobial activity against Staphylococcus aureus ATCC 6538 after 24 hrs by two-fold serial dilution method2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Computer-aided identification of novel 3,5-substituted rhodanine derivatives with activity against Staphylococcus aureus DNA gyrase.
AID205568Antibacterial activity against oxacillin resistant Staphylococcus epidermidis 012GO422000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Coumarin inhibitors of gyrase B with N-propargyloxy-carbamate as an effective pyrrole bioisostere.
AID1413266Non-competitive inhibition of full length Escherichia coli DNA gyrase ATPase activity measured for 20 mins by lactate dehydrogenase assay2018MedChemComm, Oct-01, Volume: 9, Issue:10
Identification of an auxiliary druggable pocket in the DNA gyrase ATPase domain using fragment probes.
AID1580082Antibacterial activity against wild type Acinetobacter baumannii ATCC 17978 assessed as resistant development at sub-MIC measured after 3 days of passaging by microbroth dilution method relative to control2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID717084Antibacterial activity against methicillin-resistant Staphylococcus aureus COL MB 53932012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID727371Antiproliferative activity against human SKBR3 cells2012ACS medicinal chemistry letters, Jan-01, Volume: 4, Issue:1
3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues.
AID704336Binding affinity to Escherichia coli GyrB2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
ATP-binding site of bacterial enzymes as a target for antibacterial drug design.
AID369248Increase in ompX-lacZ expression in Escherichia coli deltaompX mutant assessed as ompX upregulation after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID529392Antibacterial activity against Streptococcus pneumoniae TUPELO by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID207177Antibacterial activity against Staphylococcus aureus 011HT32000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Coumarin inhibitors of gyrase B with N-propargyloxy-carbamate as an effective pyrrole bioisostere.
AID369619Effect on ompF-lacZ fusion translation in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1167741Antimicrobial activity against Staphylococcus aureus 2375 harboring GyrA S84L mutant, GyrB R144A mutant and ParC S80Y/E84G/V693M mutant and ParE N141S mutant by broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.
AID279372Antibacterial activity against novobiocin-resistant Haemophilus influenzae ATCC 51907 with GyrB R140H mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID1454751Inhibition of bacterial DNA gyrase subunit B2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID584332Antibacterial activity against tolC, gshB deficient Escherichia coli GD1072010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID67914Minimum inhibitory concentration against Enterococcus faecalis2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID1054860Inhibition of Mycobacterium smegmatis GyrB ATPase activity expressed in Escherichia coli BL21 (DE3) after 2 hrs2013European journal of medicinal chemistry, , Volume: 70Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
AID728674Antimicrobial activity against wild type Escherichia coli O18:K1:H7 after overnight incubation2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Novel HldE-K inhibitors leading to attenuated Gram negative bacterial virulence.
AID363430Antibacterial activity against Staphylococcus aureus ATCC 29213 in absence of human serum2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
AID560224Antibacterial activity against Salmonella enterica serovar Typhimurium R200 expressing stm3031 gene deletion mutant by CLSI M7-A7 agar dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID1187835Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
AID369616Effect on ompF-lacZ fusion translation in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1164298Inhibition of Mycobacterium tuberculosis DNA gyrase-mediated relaxed pBR322 DNA supercoiling by gel electrophoresis2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
AID532764Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph-pTRC hisA:ramA mutant by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID369074Antimicrobial activity against Pseudomonas aeruginosa ATCC 13525 after 24 hrs by MTT assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Synthesis, structure and antibacterial activity of new 2-(1-(2-(substituted-phenyl)-5-methyloxazol-4-yl)-3-(2-substitued-phenyl)-4,5-dihydro-1H-pyrazol-5-yl)-7-substitued-1,2,3,4-tetrahydroisoquinoline derivatives.
AID436335Anticancer activity against TRAIL-resistant human AGS cells assessed as cell viability at 37.5 uM after 24 hrs by fluorometric microculture cytotoxicity assay in presence of 100 ng/ml TRAIL2008Journal of natural products, Nov, Volume: 71, Issue:11
Tyrosine derivatives isolated from Streptomyces sp. IFM 10937 in a screening program for TRAIL-resistance-overcoming activity.
AID717080Antibacterial activity against Haemophilus influenzae MB45722012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID564967Ratio of MIC for wild type Mycobacterium bovis BCG to MIC for wild type Mycobacterium bovis BCG in presence of 1 mg/liter CCCP2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1482550Inhibition of Streptococcus pneumoniae DNA topoisomerase 4 subunit ParC/ParE relaxation expressed in Escherichia coli BL21 (DE3) using supercoiled pBR322 DNA as substrate after 1 hr mins by agarose gel electrophoresis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID354543Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID303885Inhibition of estradiol-induced ER-mediated transcription in MELN cells by measuring luciferase activity at 200 uM after 18 hrs2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
AID396034Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID529160Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay in presence of 250 ug/ml polyethylenimine2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID303876Cell cycle arrest in MCF7 cells assessed as accumulation at S phase at 200 uM after 48 hrs by flow cytometry2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
AID1580060Antibacterial activity against Enterococcus faecium ATCC 272702019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1188155Antibacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
AID1193921Inhibition of Mycobacterium smegmatis DNA GyrB domain assessed as inhibition of inorganic phosphate release after 100 mins at room temperature by ATPase assay2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
AID369255Induction of ompX-lacZ expression in Enterobacter aerogenes ATCC 15038 assessed as total RNA content after 30 mins by RT-PCR2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1482533Antibacterial activity against TolC deficient Escherichia coli by broth microdilution method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID1415762Inhibition of Escherichia coli DNA gyrase ATPase activity using DNA as substrate after 60 mins2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID279378Antibacterial activity against Staphylococcus aureus ATCC 29213 carrying plasmid expressing GyrB R144I mutant2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID1194335Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth at 50 uM after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
AID1303185Inhibition of Staphylococcus aureus topoisomerase 4 assessed as supercoiling of relaxed pBR322 plasmid after 45 mins by ethidium bromide staining based agarose gel electrophoresis2016European journal of medicinal chemistry, Jul-19, Volume: 117New N-phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATPase inhibitors of DNA gyrase.
AID1174484Antiproliferative activity against human MCF7 cells after 72 hrs by MTS/PMS assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.
AID78694Inhibitory activity against Escherichia coli DNA gyrase2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
Fine Tuning of physico-chemical parameters to optimise a new series of novobiocin analogues.
AID206137In vitro antibacterial activity against Staphylococcus aureus 011HT1 Nov-R strain1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Synthesis and biological evaluation of coumarincarboxylic acids as inhibitors of gyrase B. L-rhamnose as an effective substitute for L-noviose.
AID564981Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring inactivated p55 gene by resazurine microtiter assay in presence of 0.5 mg/liter reserpine2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID275054Antibacterial activity against Escherichia coli W31102006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
AID534108Antibacterial activity against Pasteurella multocida pm0527 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID308455Antibacterial activity against Staphylococcus aureus UC9218 in presence of 10% HSA2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
Structure-activity relationships of bioisosteres of a carboxylic acid in a novel class of bacterial translation inhibitors.
AID363429Inhibition of Escherichia coli topoisomerase 42008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
AID571765Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID209287Compound was evaluated for antibacterial activity, against Streptococcus pyogenes 02A1UC1 strain1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B.
AID1775848Binding affinity to human LC3A expressed in Escherichia coli BL21-(DE3) by single site binding model based isothermal titration calorimetry2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.
AID340858Antimicrobial activity against wild type vancomycin-intermediate resistant Staphylococcus aureus Mu50 by microdilution assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID1446675Inhibition of Escherichia coli DNA gyrase A/DNA gyrase B supercoiling activity using relaxed pNO1 DNA as substrate after 30 mins in presence of biotin-labeled oligonucleotide by SybrGOLD staining based fluorescence assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
AID275056Antibacterial activity against Escherichia coli pTMV19 in presence of mevalonate2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
AID1678525Inhibition of Escherichia coli DNA gyrase using relaxed pNO1 plasmid DNA as substrate incubated for 30 mins by fluorescence assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Exploring the Chemical Space of Benzothiazole-Based DNA Gyrase B Inhibitors.
AID369258Effect on ompF-lacZ fusion transcription in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID205909Tested for in vitro antibacterial activity against Staphylococcus epidermidis 012GO42 oxacillin resistance phenotype2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID603462Inhibition of Staphylococcus aureus DNA Topoisomerase 4-mediated decatenation of kDNA after 30 mins by densitometry2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID765359Cell cycle arrest in human SKBR3 cells assessed as accumulation at S phase at 1000 uM after 48 hrs by flow cytometric analysis (Rvb = 19 +/- 6%)2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
AID567632Modulation proteolytic fingerprint of HSP90 in rabbit reticulocyte lysates at 10 uM after 5 mins by SDS-PAGE analysis in presence of 125 ug/ml of trypsin2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID1323398Inhibition of Staphylococcus aureus DNA topoisomerase 4 assessed as reduction in decatenation of supercoiled pNO1 DNA after 30 mins in presence of biotinylated oligonucleotide by sybrGOLD staining based fluorescence assay2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.
AID554415Antimicrobial activity against mexXY operon inactivated Pseudomonas aeruginosa isolate 3020S obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID369613Effect on ompF-lacZ fusion translation in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1264562Dose-normalized AUC in mouse at 2 mg/kg, iv by LC-MS/MS analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID531333Antibacterial activity against Pseudomonas aeruginosa PAO4290 selected after 1.0 ug/ml of azithromycin by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID554395Antimicrobial activity against Pseudomonas aeruginosa isolate 2716 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID698709Binding affinity to Escherichia coli DNA gyrase subunit B N-terminal fragment G24 measured over 120 secs by surface plasmon resonance method2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Structure-based discovery of substituted 4,5'-bithiazoles as novel DNA gyrase inhibitors.
AID554396Antimicrobial activity against Pseudomonas aeruginosa isolate 2721 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID554397Antimicrobial activity against Pseudomonas aeruginosa isolate 2729 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1698683Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial cell growth incubated for 18 hrs by CSLI based broth microdilution method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID369072Antimicrobial activity against Bacillus subtilis ATCC 6633 after 24 hrs by MTT assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Synthesis, structure and antibacterial activity of new 2-(1-(2-(substituted-phenyl)-5-methyloxazol-4-yl)-3-(2-substitued-phenyl)-4,5-dihydro-1H-pyrazol-5-yl)-7-substitued-1,2,3,4-tetrahydroisoquinoline derivatives.
AID279374Antibacterial activity against Haemophilus influenzae ATCC 51907 with GyrB T169I mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID531335Antibacterial activity against Pseudomonas aeruginosa TNP030 selected after 1.0 ug/ml of azithromycin by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID279382Antibacterial activity against Staphylococcus aureus ATCC 29213 with GyrB R144I mutation without plasmid2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID765349Cytotoxicity against ER-positive human MCF7 cells expressing low level of HER2 after 3 days by MTT assay2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
AID1335288Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 100 uM measured after 48 hrs by MTT assay relative to control2016European journal of medicinal chemistry, Nov-29, Volume: 124Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
AID69794Relative sensitizing activity against Escherichia coli was determined as a percent of pPMBN (50 ug/mL) as a control2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria.
AID1580093Toxicity in Galleria mellonella larvae MDR Acinetobacter baumannii isolate assessed as mortality at 100 mg/kg measured after 24 hrs relative to control2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1481130Inhibition of Mycobacterium tuberculosis DNA gyrase supercoiling activity using relaxed pBR322 as substrate at 10 uM after 30 mins in presence of ATP by ethidium bromide staining based agarose gel electrophoresis relative to control2017Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8
Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as Mycobacterium tuberculosis gyrase inhibitors.
AID433403Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as DNA supercoiling inhibition2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID529384Ratio of IC50 for Escherichia coli JM109 DNA gyrase subunit B by ATPase assay to IC50 for Escherichia coli JM109 DNA gyrase subunit B by supercoiling assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID1252459Inhibition of Mycobacterium smegmatis DNA gyrase B expressed in Escherichia coli BL21 (DE3) pLysS cells assessed as reduction in ATPase activity incubated for 100 mins by inorganic phosphate detection assay2015European journal of medicinal chemistry, Oct-20, Volume: 1034-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
AID433404Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as formation of DNA cleavable complex2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID501421Inhibition of Escherichia coli DNA gyraseB assessed as inhibition of pBR322 supercoiling by densitometry2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.
AID1406903Inhibition of Escherichia coli DNA topoisomerase-4 mediated decatenation using kinetoplast DNA as substrate after 30 mins agarose gel electrophoresis method2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel coumarin-pyrazole carboxamide derivatives as potential topoisomerase II inhibitors: Design, synthesis and antibacterial activity.
AID363427Inhibition of Staphylococcus aureus DNA gyrase2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
AID279381Antibacterial activity against Staphylococcus aureus ATCC 29213 with GyrB T173I mutation without plasmid2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID53448Iinhibitory activity against Staphylococcus aureus DNA gyrase2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID571882Antibacterial activity against Escherichia coli KAM32 harboring plasmid pUC18 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID1671922Inhibition of Escherichia coli DNA topoisomerase 4 using biotinylated oligonucleotide as substrate incubated for 30 mins in presence of ATP by fluorescence-based microplate reader assay2019European journal of medicinal chemistry, Apr-01, Volume: 167An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
AID531332Antibacterial activity against Pseudomonas aeruginosa PAO4290 by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID595269Inhibition of HSP90 dependent refolding of heat denatured firefly luciferase in rabbit reticulocyte lysate after 30 mins2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Identification and initial SAR of silybin: an Hsp90 inhibitor.
AID66898Antibacterial activity against Enterococcus faecalis ATCC 292122004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID1576139Inhibition of Staphylococcus aureus DNA gyrase using relaxed pNO1 plasmid DNA as substrate incubated for 30 mins by fluorescence assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
New
AID1415761Inhibition of Escherichia coli DNA gyrase assessed as inhibition of pUC19 supercoiling after 30 mins by agarose gel electrophoresis2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID303881Cell cycle arrest in MCF7 cells assessed as accumulation at G2/M phase at 200 uM after 72 hrs by flow cytometry2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
AID206679Antibacterial activity against Staphylococcus pneumoniae ATCC 496192004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID425956Antimicrobial activity against Staphylococcus aureus RN4220 harboring tetracycline-regulable expression vector pAJ96 after 24 hrs by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Intrinsic novobiocin resistance in Staphylococcus saprophyticus.
AID529387Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID557095Binding affinity to first site on human serum albumin by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1264561Antibacterial activity against Streptococcus pneumoniae 402 infected in sc dosed mouse assessed as reduction in 3 log CFU in lung compound administered as BID for 1 day measured 24 hrs after last dose2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID532580Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph mutant by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID524383Antibacterial activity against Escherichia coli NKE161 harboring deletion mutation in acrB protein, vector expressing tolC gene and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID396040Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP3 plasmid containing Enterobacter aerogenes acrR gene by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID591654Antimicrobial activity against Staphylococcus aureus Smith after 18 hrs by agar dilution method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.
AID1167740Antimicrobial activity against Staphylococcus aureus 2792 harboring wild-type GyrA and GyrB R144A mutant by broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.
AID1326672Growth inhibition of mouse RAW264.7 cells at 100 uM after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
AID1187836Cytotoxicity against mouse RAW264.7 cells at 100 uM after 48 hrs by MTT assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
AID325443Antibacterial activity against Escherichia coli K10 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID308988Inhibition of Escherichia coli D110 DNA gyrase after 30 mins by supercoiling assay2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors.
AID1520484Inhibition of human topoisomerase-2alpha using catenated DNA as substrate after 30 mins by ethidium bromide-based gel electrophoresis
AID1415741Antibacterial activity against ciprofloxacin-resistant Escherichia coli JW5503 harboring GyrB Ser464Phe mutant after 16 to 18 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID603366Antibacterial activity against methicillin-resistant Staphylococcus aureus OM584 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID369623Effect on ompF-lacZ fusion translation in marA-negative Escherichia coli CH164 mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1446679Inhibition of Escherichia coli topoisomerase 4 ParE supercoiling activity using relaxed pNO1 DNA as substrate after 30 mins in presence of biotin-labeled oligonucleotide by SybrGOLD staining based fluorescence assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
AID572151Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomegaydhE plasmid containing Escherichia coli multidrug efflux pump YdhE after 18 to 24 hrs by two fold dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID530237Antimicrobial activity against wild-type Mycobacterium smegmatis SMR5 by microplate Alamar blue assay2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis.
AID529385Inhibition of Escherichia coli K-12 DNA gyrase A expressed in Escherichia coli DC2 assessed as compound concentration required for => 4-fold induction of luxCDABE operon by reported gene assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID1264564Half-life in mouse at 2 mg/kg, iv by LC-MS/MS analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID1399843Antibacterial activity against Acinetobacter baumannii NCTC 134202018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID1406900Antibacterial activity against Listeria monocytogenes ATCC 15313 after 24 hrs by agar dilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel coumarin-pyrazole carboxamide derivatives as potential topoisomerase II inhibitors: Design, synthesis and antibacterial activity.
AID1482532Inhibition of Staphylococcus aureus topoisomerase 4 subunit ParC/ParE relaxation expressed in Escherichia coli BL21 (DE3) using supercoiled pBR322 DNA as substrate after 1 hr by agarose gel electrophoresis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID564988Antimicrobial activity against Mycobacterium bovis BCG harboring pPAZ23 carrying p27-p55 operon by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1482554Inhibition of human DNA topoisomerase 2-alpha2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID681178TP_TRANSPORTER: inhibition of ATP-depdent uptake of topotecan in membrane vesicle from BCRP-expressing PC-6/SN2-5H2 cells2004International journal of cancer, Jan-01, Volume: 108, Issue:1
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
AID501420Antimicrobial activity against methicillin-sensitive Staphylococcus aureus 209P after 24 hrs by microdilution assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.
AID537733Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1775857Displacement of sGFP-p62-LIR peptide from human N-terminal SNAP-fused LC3B by time-resolved FRET assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.
AID571926Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-N623S-Q624S mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID603457Antibacterial activity against Streptococcus pneumoniae R6 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID765345Inhibition of HSP90 in mouse 3T3-Y9-B12 cells assessed as activation of HSF1 at 1000 uM after overnight incubation by GFP reporter gene assay relative to control2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
AID554419Antimicrobial activity against mexXY operon inactivated Pseudomonas aeruginosa isolate 2721 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1698680Inhibition of Escherichia coli DNA gyrase by measuring supercoiling activity incubated for 60 mins by fluorescence based assay2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID392677Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line.
AID1054859Inhibition of Staphylococcus aureus GyrB2013European journal of medicinal chemistry, , Volume: 70Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
AID1775856Binding affinity to recombinant LC3A (unknown origin) assessed as shift of melting temperature by differential scanning fluorimetry2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.
AID1359990Inhibition of Escherichia coli C-terminal His6-tagged DNA gyrase B expressed in Escherichia coli BL21(DE3) preincubated for 10 mins followed by ATP addition measured after 30 mins by purine nucleoside phosphorylase enzyme coupled spectrophotometric method2018European journal of medicinal chemistry, Jun-25, Volume: 154New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
AID588983Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OAT12010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID1054851Inhibition of Staphylococcus aureus DNA gyrase2013European journal of medicinal chemistry, , Volume: 70Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
AID279377Antibacterial activity against Staphylococcus aureus ATCC 29213 carrying plasmid expressing GyrB T173I mutant2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID369264Effect on ompF-lacZ fusion transcription in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID774962Inhibition of human DNA topoisomerase-2alpha ATPase activity using supercoiled pUC18 DNA as substrate assessed as inorganic phosphate release at 300 uM incubated for 30 mins prior to ATP addition measured after 30 mins by malachite green phosphate assay r2013European journal of medicinal chemistry, Nov, Volume: 693-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
AID575169Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID591651Antimicrobial activity against Escherichia coli 25922 after 18 hrs by agar dilution method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.
AID1127632Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae D39 NCTC 7466 expressing ParE/GyrB K143I mutant assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method wild type Streptococcus pneumoniae2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID279357Antibacterial activity against Staphylococcus aureus ATCC 29213 with GyrB T173N and GrlB T166A mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID1303183Inhibition of Staphylococcus aureus DNA gyrase assessed as supercoiling of relaxed pBR322 plasmid after 45 mins by ethidium bromide staining based agarose gel electrophoresis2016European journal of medicinal chemistry, Jul-19, Volume: 117New N-phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATPase inhibitors of DNA gyrase.
AID554443Antimicrobial activity against mexXY operon inactivated Pseudomonas aeruginosa PAO1 by twofold macrodilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1303182Inhibition of Escherichia coli DNA gyrase assessed as supercoiling of relaxed pBR322 plasmid after 45 mins by ethidium bromide staining based agarose gel electrophoresis2016European journal of medicinal chemistry, Jul-19, Volume: 117New N-phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATPase inhibitors of DNA gyrase.
AID1415738Antibacterial activity against ciprofloxacin-resistant Escherichia coli JW5503 harboring GyrA Ser83Leu mutant after 16 to 18 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID446858Antibacterial activity against fluoroquinolone resistant Streptococcus pneumoniae SP-3765 by NCCLS method2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV.
AID1113097Antioxidant activity assessed as DPPH radical scavenging activity at 2 mg/ml after 30 min by spectrophotometric analysis2013Journal of agricultural and food chemistry, Mar-27, Volume: 61, Issue:12
Isolation and characterization of new p-Terphenyls with antifungal, antibacterial, and antioxidant activities from halophilic actinomycete Nocardiopsis gilva YIM 90087.
AID572060Antibacterial activity against abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID1127621Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae D39 NCTC 7466 expressing GyrA S81F/ParC S79F double mutant assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID1415735Antibacterial activity against gyramide-resistant Escherichia coli JW5503 harboring GyrA Phe96Leu mutant after 16 to 18 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID571766Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-N616 mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID529393Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID425955Antimicrobial activity against Staphylococcus aureus RN4220 after 24 hrs by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Intrinsic novobiocin resistance in Staphylococcus saprophyticus.
AID68219Antibacterial activity against vancomycin, teicoplanin, erythromycin resistant Enterococcus faecium2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Coumarin inhibitors of gyrase B with N-propargyloxy-carbamate as an effective pyrrole bioisostere.
AID206879Antibacterial activity against Staphylococcus aureus N1752004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1659178Inhibition of Zika virus NS2B-NS3 protease by cell based assay2020Bioorganic & medicinal chemistry letters, 03-01, Volume: 30, Issue:5
Inhibitors of the Zika virus protease NS2B-NS3.
AID584328Antibacterial activity against gshB deficient Escherichia coli JW2914-12010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID477411Antibacterial activity against MBX-1090-resistant Staphylococcus aureus isolate d20A1 after 16 to 20 hrs by broth microdilution method2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.
AID1173784Inhibition of Mycobacterium tuberculosis DNA gyrase using relaxed pBR322 as substrate after 30 mins by supercoiling assay2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
AID1303174Binding affinity to Escherichia coli DNA gyrase B by surface plasmon resonance assay2016European journal of medicinal chemistry, Jul-19, Volume: 117New N-phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATPase inhibitors of DNA gyrase.
AID69623Antibacterial activity against Escherichia coli NIHJ JC-22004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID510559Antibacterial activity against Escherichia coli AG102MB2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID369250Increase in ompX-lacZ expression in Escherichia coli JM109 assessed as ompX upregulation after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1406897Inhibition of Escherichia coli DNA topoisomerase-2 mediated DNA relaxation using supercoiled pBR322 plasmid DNA as substrate after 60 mins by ethidium bromide staining based agarose gel electrophoresis2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel coumarin-pyrazole carboxamide derivatives as potential topoisomerase II inhibitors: Design, synthesis and antibacterial activity.
AID1882172Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis and antiproliferative activity of 6BrCaQ-TPP conjugates for targeting the mitochondrial heat shock protein TRAP1.
AID1326671Inhibition of Mycobacterium tuberculosis DNA gyrase subunit A2B2 supercoiling activity using relaxed pBR322 as substrate after 30 mins in presence of ATP by agarose gel electrophoresis2016European journal of medicinal chemistry, Oct-21, Volume: 122Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
AID603463Inhibition of Escherichia coli DNA topoisomerase 4 subunit ParC/DNA topoisomerase 4 subunit ParE-mediated decatenation of kDNA by densitometry2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID207345Antibacterial activity against ofloxacin,oxacillin,erythromycin resistant Staphylococcus aureus 011GO64.2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Coumarin inhibitors of gyrase B with N-propargyloxy-carbamate as an effective pyrrole bioisostere.
AID524392Antibacterial activity against Escherichia coli NKE1369 harboring deletion mutation in acrB, acrD, mdtABC protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1337485Inhibition of human DNA topoisomerase-2alpha ATPase activity at 300 uM using supercoiled pBR322 DNA as substrate after 1 hr by malachite green dye based assay relative to control2017European journal of medicinal chemistry, Jan-05, Volume: 125Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors.
AID1415769Antibacterial activity against Escherichia coli JW5503 overexpressing gyrB in absence of IPTG induction after 16 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID1181927Cytotoxicity against human MDA-kb2 cells assessed as reduction in cell viability after 18 hrs by Promega cell titer-Glo assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.
AID1054858Inhibition of Mycobacterium tuberculosis DNA gyrase super coiling activity of relaxed pBR322 at 50 uM using ethidium bromide staining by agarose gel electrophoresis2013European journal of medicinal chemistry, , Volume: 70Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
AID206136In vitro antibacterial activity against Staphylococcus aureus 011HT1 Nov-R1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B.
AID369622Effect on ompF-lacZ fusion translation in marA-negative Escherichia coli CH164 mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID53460In vitro activity against Staphylococcus aureus DNA gyrase subunit B supercoiling, expressed as IC50 novobiocin / IC50 compound2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Coumarin inhibitors of gyrase B with N-propargyloxy-carbamate as an effective pyrrole bioisostere.
AID529510Antibacterial activity against Klebsiella pneumoniae ATCC 27736 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1471407Inhibition of recombinant human Biotin-labeled N-terminal His/Avi-tagged HSP90beta C-terminal domain (527 to 724 residues) expressed in Escherichia coli interaction with GST-tagged Cyp40 at 1 to 100 uM after 30 mins by Alphascreen assay2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Design, Synthesis, and Biological Activities of Vibsanin B Derivatives: A New Class of HSP90 C-Terminal Inhibitors.
AID303871Growth inhibition of MCF7 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
AID1335284Inhibition of Mycobacterium tuberculosis DNA gyrase assessed as inhibition of DNA supercoiling activity using relaxed pBR322 as substrate incubated for 30 mins by ethidium bromide staining based agarose gel electrophoresis2016European journal of medicinal chemistry, Nov-29, Volume: 124Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
AID531334Antibacterial activity against Pseudomonas aeruginosa TNP030 by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID564978Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring inactivated p55 gene by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1698685Antibacterial activity against Escherichia coli ATCC 25922 in presence of PAbetaN by CLSI method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID554385Antimicrobial activity against Pseudomonas aeruginosa mutGR1 overexpressing mexXY mutant by twofold macrodilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID207342Antibacterial activity tested against novobiocin resistant Staphylococcus aureus 011HT12000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Coumarin inhibitors of gyrase B with N-propargyloxy-carbamate as an effective pyrrole bioisostere.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1415737Antibacterial activity against gyramide-resistant Escherichia coli JW5503 harboring GyrB Thr508Met mutant after 16 to 18 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID520090Inhibition of reconstituted Escherichia coli DNA gyrase subunit AB assessed as reduction of DNA supercoiling activity using pBR322 DNA substrate2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
DNA gyrase from the albicidin producer Xanthomonas albilineans has multiple-antibiotic-resistance and unusual enzymatic properties.
AID1113100Antibacterial activity against Staphylococcus aureus after 24 hr by microdilution method2013Journal of agricultural and food chemistry, Mar-27, Volume: 61, Issue:12
Isolation and characterization of new p-Terphenyls with antifungal, antibacterial, and antioxidant activities from halophilic actinomycete Nocardiopsis gilva YIM 90087.
AID599178Inhibition of human topoisomerase 2alpha-mediated ATP hydrolysis at 400 uM after 30 mins by malachite green ATPase assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.
AID367050Inhibition of Escherichia coli GyrB ATPase activity assessed as inorganic phosphate release by malachite green complex formation assay2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.
AID544980Antimicrobial activity against Klebsiella pneumoniae 52OmpA2 at 100 ug/disk by disk diffusion method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Klebsiella pneumoniae OmpA confers resistance to antimicrobial peptides.
AID205684Minimum inhibitory concentration against Staphylococcus aureus Smith2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID660265Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID206139In vitro antibacterial activity against Staphylococcus aureus 011HT3 strain1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Synthesis and biological evaluation of coumarincarboxylic acids as inhibitors of gyrase B. L-rhamnose as an effective substitute for L-noviose.
AID340859Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 graR mutant microdilution assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID369260Effect on ompF-lacZ fusion transcription in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1173786Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability at 100 uM after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
AID1399857Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis H37Rv harboring katG Y155 mutant2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID554401Antimicrobial activity against Pseudomonas aeruginosa isolate 2998 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID303894Decrease in cdk4 protein level in in MCF7 cells at 200 uM after 18 hrs2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
AID369621Effect on ompF-lacZ fusion translation in marA-negative Escherichia coli CH164 mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID560222Antibacterial activity against Salmonella enterica serovar Typhimurium 01-4 by CLSI M7-A7 agar dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID1415744Antibacterial activity against novobiocin-resistant Escherichia coli CC5 harboring GyrB Arg136His mutant after 16 to 18 hrs in presence of PAbetaN by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID364887Inhibition of ABCG2 in human mitoxantrone-resistant MCF7 cells by Hoechst 33342 assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
AID529383Inhibition of Escherichia coli JM109 DNA gyrase subunit B assessed as DNA triple helix formation by supercoiling assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID1252462Inhibition of DNA gyrase GyrA/GyrB in Mycobacterium tuberculosis incubated for 30 mins assessed as reduction in supercoiling of relaxed relaxed pBR322 DNA by ethidium bromide staining based agarose gel electrophoresis method2015European journal of medicinal chemistry, Oct-20, Volume: 1034-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
AID717074Inhibition of Staphylococcus aureus DNA gyrase2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1482553Inhibition of Escherichia coli DNA gyrase subunit GyrA/GyrB R136H mutant supercoiling activity expressed in Escherichia coli BL21 (DE3) using relaxed pBR322 DNA as substrate after 1 hr mins by agarose gel electrophoresis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID717069Antibacterial activity against novobiocin-resistant Staphylococcus aureus MB 5957/A8 harboring GyrB ASP89Gly mutant2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID584325Antibacterial activity against wild type Escherichia coli BW251132010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID1495892Antiproliferative activity against human SKBR3 cells2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Exploiting polarity and chirality to probe the Hsp90 C-terminus.
AID1181924Inhibition of HSP90 in rabbit reticulocyte lysate at 250 uM after 90 mins by luciferase renaturation assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.
AID1335277Binding affinity to Escherichia coli H560 DNA gyrase B2016European journal of medicinal chemistry, Nov-29, Volume: 124Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
AID1482543Antibacterial activity against Moraxella catarrhalis A-894 by broth microdilution method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID1497256Antibacterial activity against Escherichia coli MTCC 4432018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Drug efficacy of novel 3-O-methoxy-4-halo disubstituted 5,7-dimethoxy chromans; evaluated via DNA gyrase inhibition, bacterial cell wall lesion and antibacterial prospective.
AID524264Antibacterial activity against Escherichia coli NKE158 harboring deletion mutation in acrB protein and vector expressing cpxAR gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1130036Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 after 24 hrs by two-fold serial dilution method2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Computer-aided identification of novel 3,5-substituted rhodanine derivatives with activity against Staphylococcus aureus DNA gyrase.
AID591656Antimicrobial activity against Enterococcus faecalis 6 after 18 hrs by agar dilution method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.
AID1399855Inhibition of human topoisomerase-2-mediated decatenation at 100 uM relative to control2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID206990Inhibitory activity against Staphylococcus aureus KMP92004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity.
AID584327Antibacterial activity against speE deficient Escherichia coli JW0117-12010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID520091Inhibition of reconstituted Xanthomonas albilineans DNA gyrase A and Escherichia coli DNA gyrase subunit B hybrid assessed as reduction of DNA supercoiling activity using pBR322 DNA substrate2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
DNA gyrase from the albicidin producer Xanthomonas albilineans has multiple-antibiotic-resistance and unusual enzymatic properties.
AID1167979Antimicrobial activity against methicillin-resistant Staphylococcus aureus MTCC 96 after 16 to 24 hrs by agar dilution method2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus.
AID1482535Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID1482547Inhibition of Staphylococcus aureus clinical isolate DNA topoisomerase 4 subunit ParC/ParE grlA S80F/E84V double mutant relaxation using supercoiled pBR322 DNA as substrate after 1 hr by agarose gel electrophoresis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID66899Antibacterial activity against Enterococcus faecalis KU1777 (VRE)2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID704335Inhibition of EnvZ by strand-transfer assay2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
ATP-binding site of bacterial enzymes as a target for antibacterial drug design.
AID1167976Inhibition of Staphylococcus aureus DNA gyrase B ATPase activity2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus.
AID571764Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring acrB::rpsLneo mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID1424097Antibacterial activity against methicillin-resistant Staphylococcus aureus2017Journal of natural products, 04-28, Volume: 80, Issue:4
Antibacterial Compounds from Marine Bacteria, 2010-2015.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID529386Inhibition of Escherichia coli K-12 DNA sulA expressed in Escherichia coli DC2 assessed as compound concentration required for => 4-fold induction of luxCDABE operon by reported gene assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID1863570Cytoprotective activity against mouse N2a cells assessed as increase in mitochondrial ATP production at 100 to 1000 nM measured by Seahorse extracellular flux analyzer based assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70Synthesis and evaluation of 3'- and 4'-substituted cyclohexyl noviomimetics that modulate mitochondrial respiration.
AID1415746Antibacterial activity against novobiocin-resistant Escherichia coli LE316 harboring GyrB Arg136Val mutant after 16 to 18 hrs in presence of PAbetaN by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID303875Cell cycle arrest in MCF7 cells assessed as accumulation at G0/G1 phase at 200 uM after 48 hrs by flow cytometry2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
AID69471Minimum inhibitory concentration against Escherichia coli 259222004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID1471426Inhibition of recombinant human Biotin-labeled N-terminal His/Avi-tagged HSP90beta C-terminal domain (527 to 724 residues) expressed in Escherichia coli interaction with GST-tagged Cyp40 at 500 uM after 30 mins by Alphascreen assay2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Design, Synthesis, and Biological Activities of Vibsanin B Derivatives: A New Class of HSP90 C-Terminal Inhibitors.
AID369253Increase in ompX-lacZ expression in Enterobacter aerogenes ATCC 15038 assessed as increase in beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID381842Antibacterial activity against Escherichia coli ATCC 352182008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis, structure and antibacterial activity of novel 1-(5-substituted-3-substituted-4,5-dihydropyrazol-1-yl)ethanone oxime ester derivatives.
AID567633Modulation proteolytic fingerprint of HSP90 in rabbit reticulocyte lysates assessed as formation of 40 kDa protein at 20 mM after 5 mins by SDS-PAGE analysis in presence of 50 ug/ml of trypsin2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID532766Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph-pTRC hisA:ramA mutant by broth dilution method in presence of chlorpromzine2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID557094Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 1.6% gamma globulin2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1775849Binding affinity to human LC3B expressed in Escherichia coli BL21-(DE3) by single site binding model based isothermal titration calorimetry2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.
AID572147Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomeganorM plasmid containing Neisseria gonorrhoeae multidrug efflux pump NorM after 18 to 24 hrs by two fold dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID369257Effect on ompF-lacZ fusion transcription in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID591655Antimicrobial activity against Staphylococcus epidermidis 16/2 after 18 hrs by agar dilution method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.
AID572062Antibacterial activity against abeS sigma abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID1156898Antiproliferative activity against ER-positive human MCF7 cells assessed as cell viability at 0.1 mM after 72 hrs by MTT assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors.
AID530052Antimicrobial activity against Staphylococcus aureus RN4220 expressing gyrB D437N mutant gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
AID571885Antibacterial activity against Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene by CLSI broth microdilution method in presence of 25 ug/ml efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID205816Compound was tested in vitro for antibacterial activity against Staphylococcus aureus Coum-R2000Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8
Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors.
AID1167743Antimicrobial activity against Streptococcus pneumoniae 2800 harboring GyrB K143I/T172A mutant by broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1167739Antimicrobial activity against wild-type Staphylococcus aureus 516 by broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID206878Antibacterial activity against Staphylococcus aureus KMP9 (MRSA)2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID529382Inhibition of Escherichia coli JM109 DNA gyrase subunit B assessed as ATP hydrolysis by ATPase assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID1127620Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae D39 NCTC 7466 expressing GyrB K143A/ParE T172A double mutant assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID1415743Antibacterial activity against Escherichia coli HB101 after 16 to 18 hrs in presence of PAbetaN by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID606875Inhibition of Hsp90 interaction with [35S]His-tagged HRI K199R mutant in reticulocyte lysate assessed as coadsorbed Hsp90 at 4 mM after 40 mins by SDS-PAGE and Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID325444Antibacterial activity against Escherichia coli K12 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID621293Antibacterial activity against Staphylococcus aureus ATCC 29213 after 18 to 24 hrs by CLSI M100-S17 method2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Mannich reaction derivatives of novobiocin with modulated physiochemical properties and their antibacterial activities.
AID93908Relative sensitizing activity against Klebsiella pneumoniae was determined as a percent of pPMBN (50 ug/mL) as a control2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria.
AID524388Antibacterial activity against Escherichia coli NKE1366 harboring deletion mutation in acrB and vector expressing mdtABC gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1193922Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
AID1359997Inhibition of Escherichia coli C-terminal His6-tagged DNA gyrase B expressed in Escherichia coli BL21(DE3) assessed as residual activity at 1 uM preincubated for 10 mins followed by ATP addition measured after 30 mins by purine nucleoside phosphorylase en2018European journal of medicinal chemistry, Jun-25, Volume: 154New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
AID279359Antibacterial activity against Streptococcus pneumoniae ATCC BAA-255 after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID564979Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring inactivated p55 gene by resazurine microtiter assay in presence of 1 mg/liter CCCP2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1678530Inhibition of Staphylococcus aureus DNA topoisomerase 4 using supercoiled pNO1 plasmid DNA as substrate incubated for 30 mins by fluorescence assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Exploring the Chemical Space of Benzothiazole-Based DNA Gyrase B Inhibitors.
AID1413263Inhibition of full length Escherichia coli DNA gyrase ATPase activity at 1 mM measured for 20 mins by lactate dehydrogenase assay relative to control2018MedChemComm, Oct-01, Volume: 9, Issue:10
Identification of an auxiliary druggable pocket in the DNA gyrase ATPase domain using fragment probes.
AID564984Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring pPAZ23 carrying p27-p55 operon by resazurine microtiter assay in presence of 0.1 mg/liter valinomycin2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1202995Antiproliferative activity against human SKBR3 cells2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors.
AID1775855Binding affinity to human LC3A expressed in Escherichia coli BL21-(DE3) by isothermal titration calorimetry2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.
AID369252Increase in ompX-lacZ expression in Enterobacter aerogenes ATCC 15038 assessed as ompX upregulation after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID425954Antimicrobial activity against Staphylococcus saprophyticus ATCC 15305 after 24 hrs by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Intrinsic novobiocin resistance in Staphylococcus saprophyticus.
AID529389Antibacterial activity against Staphylococcus aureus 80CR5 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID774963Inhibition of human DNA topoisomerase-2alpha ATPase activity using supercoiled pUC18 DNA as substrate assessed as inorganic phosphate release at 200 uM incubated for 30 mins prior to ATP addition measured after 30 mins by malachite green phosphate assay r2013European journal of medicinal chemistry, Nov, Volume: 693-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
AID207647Antibacterial activity against Staphylococcus aureus novobiocin resistant strain 011HT11999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B.
AID1310935Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.
AID532573Antimicrobial activity against Salmonella serovar Typhimurium SL1344 by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID78713In vitro inhibition of supercoiling activity of Escherichia coli DNA gyrase as the ratio of IC50 of Novobiocin of the compound1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B.
AID704337Inhibition of Escherichia coli His6-tagged ParC/ParE expressed in baculovirus-infected Sf9 cells by gel electrophoresis2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
ATP-binding site of bacterial enzymes as a target for antibacterial drug design.
AID1233814Inhibition of Escherichia coli DNA topoisomerase 4 using kinetoplast DNA as substrate by decatenation assay2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.
AID1482538Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by broth microdilution method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID531337Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 selected after 1.0 ug/ml of azithromycin by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID554387Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY operon by twofold macrodilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID572150Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBAD plasmid after 18 to 24 hrs by two fold dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID1127616Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae D39 NCTC 7466 expressing ParE/GyrB T172A mutant assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID113358In vivo effective dose was determined in septicaemic mice (Staphylococcus aureus Smith) when administration iv2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID279354Antibacterial activity against Staphylococcus aureus ATCC 29213 with GyrB T173N mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID1576141Inhibition of Escherichia coli DNA topoisomerase 4 using supercoiled pNO1 plasmid DNA as substrate incubated for 30 mins by fluorescence assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
New
AID501423Antimicrobial activity against Escherichia coli K-12 after 24 hrs by microdilution assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.
AID369262Effect on ompF-lacZ fusion transcription in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID501416Antimicrobial activity against methicillin-resistant Staphylococcus aureus OM481 after 24 hrs by microdilution assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.
AID1264557Antibacterial activity against Streptococcus pneumoniae for 18 to 24 hrs by broth microdilution method2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID1873195Inhibition of ABCG2 (unknown origin) expressed human PC-6/SN2-5 cells membrane vesicle mediated topotecan transport by HPLC analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID554423Antimicrobial activity against mexXY operon inactivated Pseudomonas aeruginosa isolate 2933 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1415742Antibacterial activity against Escherichia coli HB101 after 16 to 18 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID26335pKa value was determined2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
Fine Tuning of physico-chemical parameters to optimise a new series of novobiocin analogues.
AID537735Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID557093Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1576143Inhibition of Staphylococcus aureus DNA topoisomerase 4 using supercoiled pNO1 plasmid DNA as substrate incubated for 30 mins by fluorescence assay2019MedChemComm, Jun-01, Volume: 10, Issue:6
New
AID1054856Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by MABA assay2013European journal of medicinal chemistry, , Volume: 70Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
AID544979Antimicrobial activity against Klebsiella pneumoniae 52145 at 100 ug/disk by disk diffusion method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Klebsiella pneumoniae OmpA confers resistance to antimicrobial peptides.
AID1233816Inhibition of Escherichia coli DNA gyrase using relaxed pBR322 DNA as substrate after 3 hrs by DNA super-coiling assay2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.
AID354542Inhibition of tubulin polymerization in rat C6 cells at 50 ug/mL to 2.5 mg/mL after 4 hrs1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID554386Antimicrobial activity against mexXY deficient ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant by twofold macrodilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1482592Resistance index, ratio of IC50 for Escherichia coli DNA gyrase subunit GyrA/GyrB R136H mutant supercoiling activity to IC50 for Escherichia coli N-terminal His6-tagged DNA gyrase subunit GyrA/GyrB supercoiling activity2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID369267Effect on ompF-lacZ fusion transcription in marA-negative Escherichia coli CH164 mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID229527Ratio of IC50 compared to novobiocin in Escherichia coli DNA gyrase supercoiling assay1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B.
AID325449Antibacterial activity against Staphylococcus aureus ATCC 3556 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID207642Antibacterial activity against Staphylococcus aureus 011HT3 strain1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B.
AID363431Antibacterial activity against Staphylococcus aureus ATCC 29213 in presence of human serum2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
AID1127579Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae D39 NCTC 7466 expressing GyrB T172A/ParE T172A double mutant assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method wild type Streptococcus pneu2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID1756502Inhibition of Staphylococcus aureus topoisomerase assessed as reduction in relaxation of supercoiled pNO1 DNA measured after 30 mins by fluorescence assay2021European journal of medicinal chemistry, Mar-05, Volume: 213New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.
AID667505Inhibition of Escherichia coli R67 DHFR2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase.
AID1054853Inhibition of Pseudomonas aeruginosa DNA gyrase2013European journal of medicinal chemistry, , Volume: 70Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
AID564974Antimicrobial activity against Mycobacterium bovis BCG by resazurine microtiter assay in presence of 1 mg/liter CCCP2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1326673Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
AID369077Inhibition of Bacillus subtilis DNA gyrase2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Synthesis, structure and antibacterial activity of new 2-(1-(2-(substituted-phenyl)-5-methyloxazol-4-yl)-3-(2-substitued-phenyl)-4,5-dihydro-1H-pyrazol-5-yl)-7-substitued-1,2,3,4-tetrahydroisoquinoline derivatives.
AID529885Antibacterial activity against Staphylococcus aureus RN4220 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
AID381841Antibacterial activity against Bacillus subtilis ATCC 66332008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis, structure and antibacterial activity of novel 1-(5-substituted-3-substituted-4,5-dihydropyrazol-1-yl)ethanone oxime ester derivatives.
AID325446Antibacterial activity against Salmonella enterica serovar Typhimurium LT2 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID564986Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring pPAZ23 carrying p27-p55 operon by resazurine microtiter assay in presence of 0.5 mg/liter reserpine2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID308996Antibacterial activity against ampicillin, trimethoprim and vancomycin-resistant Enterococcus faecium vanA E23-8 by twofold agar dilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors.
AID489700Antiproliferative activity against human ER deficient SKBR3 cells over expressing HER22010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues.
AID279366Antibacterial activity against Enterococcus faecalis ATCC 29212 with GyrB T167A mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID308991Antibacterial activity against Staphylococcus aureus Smith by twofold agar dilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors.
AID1413267Inhibition of recombinant Escherichia coli DNA gyrase assessed as reduction of topological transition of relaxed pHTO-1 to its negatively supercoiled form at 1 mM after 30 mins by agarose gel electrophoresis2018MedChemComm, Oct-01, Volume: 9, Issue:10
Identification of an auxiliary druggable pocket in the DNA gyrase ATPase domain using fragment probes.
AID1415739Antibacterial activity against ciprofloxacin-resistant Escherichia coli JW5503 harboring GyrA Asp87Gly mutant after 16 to 18 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID1310936Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.
AID347462Inhibition of DNA gyrase assessed as pBR322 DNA relaxation at 5 uM2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Synthesis and antibacterial property of quinolines with potent DNA gyrase activity.
AID524382Antibacterial activity against Escherichia coli NKE160 harboring deletion mutation in acrB protein and vector expressing tolC gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1415770Antibacterial activity against Escherichia coli JW5503 overexpressing gyrA/gyrB in presence of IPTG induction after 16 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID1756500Inhibition of Staphylococcus aureus DNA gyrase assessed reduction in relaxation of supercoiled pNO1 DNA measured after 30 mins by fluorescence assay2021European journal of medicinal chemistry, Mar-05, Volume: 213New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.
AID554391Antimicrobial activity against Pseudomonas aeruginosa isolate 615R obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID369620Effect on ompF-lacZ fusion translation in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID369617Effect on ompF-lacZ fusion translation in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID303879Cell cycle arrest in MCF7 cells assessed as accumulation at G0/G1 phase at 200 uM after 72 hrs by flow cytometry2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
AID1406899Antibacterial activity against Staphylococcus aureus ATCC 12600 after 24 hrs by agar dilution method2018European journal of medicinal chemistry, Sep-05, Volume: 157Novel coumarin-pyrazole carboxamide derivatives as potential topoisomerase II inhibitors: Design, synthesis and antibacterial activity.
AID1671927Inhibition of Escherichia coli DNA gyrase using biotinylated oligonucleotide as substrate incubated for 30 mins in presence of ATP by fluorescence-based microplate reader assay2019European journal of medicinal chemistry, Apr-01, Volume: 167An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
AID525125Suppression of drug resistance development in Staphylococcus aureus RN4220 assessed as assessed as prolonged length of subculture to develop Linezolid resistance at 0.25 times MIC2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.
AID529163Antibacterial activity against Pseudomonas aeruginosa 100609 assessed as reduction in bacterial count at 0.25 times MIC after 9 hrs by time-kill assay in presence of 250 ug/ml polyethylenimine relative to control2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID283559Antibacterial activity against Escherichia coli AG102MB after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1335222Inhibition of Escherichia coli DNA topoisomerase 4 decatenation activity using kinetoplast DNA as substrate after 60 mins by agarose gel electrophoresis2016European journal of medicinal chemistry, Nov-10, Volume: 123Quinolino[3,4-b]quinoxalines and pyridazino[4,3-c]quinoline derivatives: Synthesis, inhibition of topoisomerase IIα, G-quadruplex binding and cytotoxic properties.
AID1156893Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors.
AID537734Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID564969Upregulation of p55 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID524389Antibacterial activity against Escherichia coli NKE1367 harboring deletion mutation in acrB, mdtABC protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1194330Inhibition of Mycobacterium smegmatis GyrB ATPase activity expressed in Escherichia coli BL21 (DE3) pLysS cells after 100 mins by inorganic phosphate release detection based malachite green reagent assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
AID1272964Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth at 50 uM after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.
AID308992Antibacterial activity against methicillin and quinolones-resistant Staphylococcus aureus Smith QR54 by twofold agar dilution method2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors.
AID1756499Inhibition of Escherichia coli DNA gyrase assessed as reduction in relaxation of supercoiled pNO1 DNA measured after 30 mins by fluorescence assay2021European journal of medicinal chemistry, Mar-05, Volume: 213New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.
AID381844Antibacterial activity against Staphylococcus aureus ATCC 65382008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis, structure and antibacterial activity of novel 1-(5-substituted-3-substituted-4,5-dihydropyrazol-1-yl)ethanone oxime ester derivatives.
AID1174483Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS/PMS assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.
AID501419Antimicrobial activity against methicillin-resistant Staphylococcus aureus COL after 24 hrs by microdilution assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.
AID564968Upregulation of p27 gene expression in Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1399853Inhibition of Mycobacterium tuberculosis DNA gyrase activity2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID1272956Inhibition of Mycobacterium tuberculosis DNA gyrase assessed as inhibition of DNA supercoiling after 30 mins by electrophoresis2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.
AID529161FIC index, ratio of MIC for Pseudomonas aeruginosa 100609 in presence of 250 ug/ml polyethylenimine to MIC for Pseudomonas aeruginosa 1006092008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID554392Antimicrobial activity against Pseudomonas aeruginosa isolate 3020S obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1130033Antimicrobial activity against Staphylococcus aureus ISP 794 after 24 hrs by two-fold serial dilution method2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Computer-aided identification of novel 3,5-substituted rhodanine derivatives with activity against Staphylococcus aureus DNA gyrase.
AID347461Inhibition of DNA gyrase assessed as pBR322 DNA relaxation at 1 uM2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Synthesis and antibacterial property of quinolines with potent DNA gyrase activity.
AID369254Increase in ompX-lacZ expression in marA-negative Escherichia coli CH164 mutant assessed as beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID717071Inhibition of Escherichia coli ATPase activity of topoisomerase-42012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID765352Inhibition of HSP90 in human SKBR3 cells assessed as aggregation of intracellular HER2 at 1000 uM after 18 hrs by DAPI staining-based immunofluorescence microscopic analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
AID1245291Inhibition of Staphylococcus aureus Topoisomerase 4 assessed as inhibition of supercoiled pBR322 DNA relaxation after 30 mins by agarose gel electrophoresis2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID433402Inhibition of Mycobacterium leprae DNA gyrase subunit A A91V mutant assessed as DNA supercoiling inhibition2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID78718IC50 was determined for gyrase B of Staphylococcus aureus against novobiocin (0.5 mg/mL) as reference; IC50nov/IC50comp2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID1054852Inhibition of Escherichia coli DNA gyrase2013European journal of medicinal chemistry, , Volume: 70Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
AID303877Cell cycle arrest in MCF7 cells assessed as accumulation at G2/M phase at 200 uM after 48 hrs by flow cytometry2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
AID1726505Binding affinity to HSP90 C-terminal domain (unknown origin) by biochemical assay2021RSC medicinal chemistry, Mar-01, Volume: 12, Issue:3
Using NMR to identify binding regions for N and C-terminal Hsp90 inhibitors using Hsp90 domains.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID524386Antibacterial activity against Escherichia coli NKE157 harboring deletion mutation in acrB, acrD protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID501417Antimicrobial activity against methicillin-resistant Staphylococcus aureus OM584 after 24 hrs by microdilution assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.
AID1399837Antibacterial activity against Staphylococcus aureus ATCC 292132018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID584331Antibacterial activity against tolC, speE deficient Escherichia coli GD1062010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID591653Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by agar dilution method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.
AID206680Antibacterial activity against Staphylococcus pneumoniae KT2524 (PRSP)2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID1775853Binding affinity to human GABARAPL2 expressed in Escherichia coli T7 by single site binding model based isothermal titration calorimetry2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.
AID572059Antibacterial activity against Acinetobacter baumannii AC0037 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID1173783Inhibition of purified Mycobacterium smegmatis GyrB at 50 to 100 uM after 100 mins by ATPase assay2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
AID230597Range for minimum inhibitory concentration against Enterococcus faecium; 2-82004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID1399847Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by agar dilution method2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID564985Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring pPAZ23 carrying p27-p55 operon by resazurine microtiter assay in presence of 1 mg/liter CCCP2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1113094Antioxidant activity assessed as ABTS radical scavenging activity at 0.5 mg/ml after 5 min by spectrophotometric analysis2013Journal of agricultural and food chemistry, Mar-27, Volume: 61, Issue:12
Isolation and characterization of new p-Terphenyls with antifungal, antibacterial, and antioxidant activities from halophilic actinomycete Nocardiopsis gilva YIM 90087.
AID279360Antibacterial activity against novobiocin-resistant Streptococcus pneumoniae ATCC BAA-255 with GyrB S127L mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID369418Effect on ompF-lacZ fusion translation in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID498878Antimicrobial activity against Escherichia coli RAM1129 by agar dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Biologic activities of the TolC-like protein of Neisseria meningitidis as assessed by functional complementation in Escherichia coli.
AID1459325Inhibition of Staphylococcus aureus DNA gyrase using relaxed pBR322 DNA as substrate after 3 hrs by agarose electrophoresis2017European journal of medicinal chemistry, Jan-05, Volume: 125Linker-switch approach towards new ATP binding site inhibitors of DNA gyrase B.
AID53329Maximum noneffective concentration against Escherichia coli DNA gyrase2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID621295Antibacterial activity against Francisella tularensis Schu S4 after 18 to 24 hrs by CLSI M100-S17 method2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Mannich reaction derivatives of novobiocin with modulated physiochemical properties and their antibacterial activities.
AID532765Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph-pTRC hisA:ramA mutant by broth dilution method in presence of IPTG2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID67751Minimum inhibitory concentration against Enterococcus faecalis 62004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID1482539Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae A-70 harboring topoisomerase gyrA S81F mutant/parc S79F mutant/parE I440V mutant by broth microdilution method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID1113101Antifungal activity against Magnaporthe oryzae after 4 days by microdilution method2013Journal of agricultural and food chemistry, Mar-27, Volume: 61, Issue:12
Isolation and characterization of new p-Terphenyls with antifungal, antibacterial, and antioxidant activities from halophilic actinomycete Nocardiopsis gilva YIM 90087.
AID369618Effect on ompF-lacZ fusion translation in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1482540Antibacterial activity against Streptococcus pyogenes ATCC 19615 by broth microdilution method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID392675Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in retinoic acid-differentiated human SH-SY5Y cells assessed as lactate dehydrogenase release2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line.
AID529513Antibacterial activity against Pseudomonas aeruginosa K799/61 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID68233Compound was tested in vitro for antibacterial activity against Enterococcus faecium vanA E23-82000Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8
Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors.
AID206138In vitro antibacterial activity against Staphylococcus aureus 011HT31999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B.
AID554399Antimicrobial activity against Pseudomonas aeruginosa isolate 2858 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1698682Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial cell growth incubated for 18 hrs by CSLI based broth microdilution method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID603362Antibacterial activity against vancomycin resistant Enterococcus FN-1 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID1188153Inhibition of 6-His-tagged Mycobacterium smegmatis GyrB expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 100 mins in presence of ATP by malachite green dye based ATP assay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
AID1580092Antibacterial activity against novobiocin and test compound-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages in presence of novobiocin by checkerboard assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID765358Inhibition of HSP90 in human SKBR3 cells assessed as depletion of cell surface HER2 protein level at 100 uM after 18 hrs by immunofluorescence-based flow cytometric analysis relative to control2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
AID1459318Inhibition of Escherichia coli ATCC 25922 DNA gyrase B using relaxed pNO1 DNA as substrate incubated for 30 mins and measured by sybrGOLD staining based fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Linker-switch approach towards new ATP binding site inhibitors of DNA gyrase B.
AID51924Effect on cross resistance of chinese hamster cells resistant to Actinomycin D.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1127618Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae D39 NCTC 7466 expressing GyrB/ParE T172A mutant assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID603365Antibacterial activity against methicillin-resistant Staphylococcus aureus OM481 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID206167Tested for in vitro antibacterial activity against Staphylococcus aureus 011 GO64 ofloxacin oxacillin erythromycin resistance phenotype2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID363432Antibacterial activity against Streptococcus pneumoniae ATCC 100152008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
AID436160Anticancer activity against TRAIL-resistant human AGS cells assessed as cell viability at 75 uM after 24 hrs by fluorometric microculture cytotoxicity assay in presence of 100 ng/ml TRAIL2008Journal of natural products, Nov, Volume: 71, Issue:11
Tyrosine derivatives isolated from Streptomyces sp. IFM 10937 in a screening program for TRAIL-resistance-overcoming activity.
AID621294Antibacterial activity against Mycobacterium tuberculosis H37Rv after 18 to 24 hrs by CLSI M100-S17 method2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Mannich reaction derivatives of novobiocin with modulated physiochemical properties and their antibacterial activities.
AID1173785Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 7 days by MABA assay2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
AID1513551Antiproliferative activity against human SKBR3 cells after 72 hrs by MTS assay2019Journal of medicinal chemistry, 01-10, Volume: 62, Issue:1
Allosteric Modulators of HSP90 and HSP70: Dynamics Meets Function through Structure-Based Drug Design.
AID1775850Binding affinity to human LC3C expressed in Escherichia coli BL21-(DE3) by single site binding model based isothermal titration calorimetry2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.
AID774961Inhibition of human DNA topoisomerase-2alpha ATPase activity using supercoiled pUC18 DNA as substrate assessed as inorganic phosphate release at 400 uM incubated for 30 mins prior to ATP addition measured after 30 mins by malachite green phosphate assay r2013European journal of medicinal chemistry, Nov, Volume: 693-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
AID1775851Binding affinity to human GABARAP expressed in Escherichia coli T7 by single site binding model based isothermal titration calorimetry2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.
AID1187834Inhibition of Mycobacterium tuberculosis GyrA/GyrB using relaxed pBR322 as substrate after 30 mins by DNA supercoiling assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
AID1399839Antibacterial activity against Mycobacterium smegmatis ATCC 194202018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID96073Antimicrobial activity against Klebsiella pneumoniae (Klebsiella pneumoniae)2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria.
AID363433Antibacterial activity against Haemophilus influenzae ATCC 519072008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1446688Inhibition of Staphylococcus aureus DNA gyrase supercoiling activity using relaxed pBR322 DNA as substrate after 45 mins by ethidium-bromide staining based agarose gel electrophoresis2017European journal of medicinal chemistry, Apr-21, Volume: 130Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
AID603368Antibacterial activity against methicillin-resistant Staphylococcus aureus COL after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID206169Tested for in vitro antibacterial activity against Staphylococcus aureus 011 HT1 novobiocin resistance phenotype2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID1482541Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID1580073Bacteriostatic activity against Acinetobacter baumannii ATCC 17978 at 50.4 uM in LB media after 24 hrs by time-kill assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID57195Inhibitory activity against human DNA topoisomerase II2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity.
AID654692Inhibition of Escherichia coli DNA gyrase B using relaxed pNO1 as substrate after 30 mins by fluorimetry2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
In silico discovery and biophysical evaluation of novel 5-(2-hydroxybenzylidene) rhodanine inhibitors of DNA gyrase B.
AID1580068Bacteriostatic activity against Pseudomonas aeruginosa PAO1 at 50.4 uM in LB media after 24 hrs by time-kill assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1335283Inhibition of Mycobacterium smegmatis DNA gyrase B expressed in BL21(DE3)pLysS cells assessed as inhibition of DNA supercoiling activity in presence of ATP measured after 30 mins by malachite green dye based assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
AID1167744Antimicrobial activity against Streptococcus pneumoniae 2485 harboring GyrA S81F mutant, GyrB D160E/T329A mutant and ParC S79F mutant by broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.
AID571767Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-M626I mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID1754440Inhibition of HSP90alpha C-terminal domain (unknown origin) assessed as reduction in HSP90 binding to PPID at 100 uM by AlphaScreen microplate reader analysis2021Bioorganic & medicinal chemistry letters, 08-01, Volume: 45Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer.
AID1461760Inhibition of human DNA topoisomerase 2 ATPase activity at 300 mM by Topo-2 ATPase assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Recent synthetic and medicinal perspectives of tryptanthrin.
AID621247Displacement of novobiocin-TRX from Francisella tularensis Schu S4 gyraseB by fluorescence polarization assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Mannich reaction derivatives of novobiocin with modulated physiochemical properties and their antibacterial activities.
AID207788Compound was evaluated for its minimum inhibitory concentration against Staphylococcus aureus2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
Fine Tuning of physico-chemical parameters to optimise a new series of novobiocin analogues.
AID279353Antibacterial activity against Staphylococcus aureus ATCC 29213 after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID206134In vitro antibacterial activity against Staphylococcus aureus 011GO76 OfloOxaEry-R strain1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Synthesis and biological evaluation of coumarincarboxylic acids as inhibitors of gyrase B. L-rhamnose as an effective substitute for L-noviose.
AID1266237Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by alamar blue assay2016Bioorganic & medicinal chemistry, Jan-01, Volume: 24, Issue:1
Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
AID1399849Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by agar dilution method2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID564976Antimicrobial activity against Mycobacterium bovis BCG by resazurine microtiter assay in presence of 0.5 mg/liter reserpine2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID69937Antimicrobial activity against Escherichia coli (Escherichia coli)2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria.
AID1360003Inhibition of Staphylococcus aureus topoisomerase-4 assessed as residual activity preincubated for 10 mins followed by ATP addition measured after 30 mins by purine nucleoside phosphorylase enzyme coupled spectrophotometric method2018European journal of medicinal chemistry, Jun-25, Volume: 154New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
AID1851369Inhibition of Escherichia coli topoisomerase 4 assessed as relaxation of supercoiled plasmid pBR322 DNA and measured after 30 mins2022RSC medicinal chemistry, Jul-20, Volume: 13, Issue:7
AID1558330Cytotoxicity against African green monkey Vero cells by MTT assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID660264Ratio of MIC for wild type Escherichia coli HS414 to MIC for acrB-deficient Escherichia coli HS832 by agar dilution method2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID369076Inhibition of Staphylococcus aureus DNA gyrase2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Synthesis, structure and antibacterial activity of new 2-(1-(2-(substituted-phenyl)-5-methyloxazol-4-yl)-3-(2-substitued-phenyl)-4,5-dihydro-1H-pyrazol-5-yl)-7-substitued-1,2,3,4-tetrahydroisoquinoline derivatives.
AID1497255Antibacterial activity against Klebsiella pneumoniae MTCC 5302018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Drug efficacy of novel 3-O-methoxy-4-halo disubstituted 5,7-dimethoxy chromans; evaluated via DNA gyrase inhibition, bacterial cell wall lesion and antibacterial prospective.
AID564973Antimicrobial activity against Mycobacterium bovis BCG by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID433401Inhibition of Mycobacterium leprae DNA gyrase subunit A G89C mutant assessed as DNA supercoiling inhibition2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID56395Iinhibitory activity against human DNA topoisomerase II2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID53457In vitro activity against Escherichia coli DNA gyrase subunit B supercoiling, expressed as IC50 novobiocin / IC50 compound2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
Coumarin inhibitors of gyrase B with N-propargyloxy-carbamate as an effective pyrrole bioisostere.
AID524390Antibacterial activity against Escherichia coli NKE1316 harboring deletion mutation in acrB, acrD and mdtABC protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1678528Inhibition of Escherichia coli DNA topoisomerase 4 using supercoiled pNO1 plasmid DNA as substrate incubated for 30 mins by fluorescence assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Exploring the Chemical Space of Benzothiazole-Based DNA Gyrase B Inhibitors.
AID529396Antibacterial activity against Escherichia coli UB1005 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID396039Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pACYC184 plasmid by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID554393Antimicrobial activity against Pseudomonas aeruginosa isolate 3020R obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID396037Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID433579Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A A91V mutant assessed as formation of DNA cleavable complex2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1127631Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae D39 NCTC 7466 expressing ParE/GyrB T172A mutant assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method relative to wild type Streptococcus pneum2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID433578Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A G89A mutant assessed as formation of DNA cleavable complex2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID603458Antibacterial activity against Pseudomonas aeruginosa PAO1 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID717085Antibacterial activity against methicillin-sensitive Staphylococcus aureus MB 2865 in presence of 50% human serum2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID56394Iinhibitory activity against Staphylococcus aureus DNA topoisomerase IV2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID571925Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-G616N mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID446861Antibacterial activity against Streptococcus pneumoniae D39 by NCCLS method2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV.
AID57380Inhibitory activity against Escherichia coli DNA topoisomerase IV2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity.
AID717070Antibacterial activity against wild type Staphylococcus aureus MB 59572012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1558328Inhibition of NS2B-NS3 protease in Zika virus Puerto Rico/PRVABC5 infected in human Huh7 cells assessed as antiviral activity measured 48 hrs post infection by RT-PCR method2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID209438Compound was tested in vitro for antibacterial activity against Streptococcus pyogenes beta152000Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8
Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors.
AID206882Antibacterial activity against Staphylococcus aureus RN42202004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.
AID1329929Inhibition of Escherichia coli DNA gyrase supercoiling activity using relaxed pNO1 as substrate after 30 mins in presence of biotin-labeled oligonucleotide and ATP by SybrGOLD staining based fluorescence assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Design, synthesis and biological evaluation of 4,5-dibromo-N-(thiazol-2-yl)-1H-pyrrole-2-carboxamide derivatives as novel DNA gyrase inhibitors.
AID1127622Antibacterial activity against fluoroquinolone-resistant Streptococcus pneumoniae D39 NCTC 7466 expressing GyrA S81Y/ParC S79F double mutant assessed as growth inhibition after 18 to 24 hrs by CLSI broth microdilution method2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID498879Antimicrobial activity against Escherichia cloi RAM1129 transfected with pGCC4 containg IPTG-inducible lacZ promoter by agar dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Biologic activities of the TolC-like protein of Neisseria meningitidis as assessed by functional complementation in Escherichia coli.
AID1871437Antibacterial activity against beta lactamase positive Staphylococcus aureus ATCC 25923 assessed as zone of inhibition at 0.5 mg/ml incubated for 18 hrs by Kirby-Bauer disk diffusion method2022European journal of medicinal chemistry, Jan-05, Volume: 227Coumarin-benzimidazole hybrids: A review of developments in medicinal chemistry.
AID279365Antibacterial activity against Enterococcus faecalis ATCC 29212 with ParE T169A mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID564980Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring inactivated p55 gene by resazurine microtiter assay in presence of 0.1 mg/liter valinomycin2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1775846Binding affinity to recombinant LC3B (unknown origin) assessed as shift of melting temperature by differential scanning fluorimetry2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface.
AID595164Binding affinity at Hsp90 C-terminal region in human SKBr3 cells2010ACS medicinal chemistry letters, Jul-13, Volume: 1, Issue:7
Synthesis and Evaluation of Noviose Replacements on Novobiocin that Manifest Anti-proliferative Activity.
AID554416Antimicrobial activity against mexXY operon inactivated Pseudomonas aeruginosa isolate 3020R obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID205819Compound was tested in vitro for antibacterial activity against Staphylococcus aureus Smith2000Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8
Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors.
AID1167742Antimicrobial activity against wild-type Streptococcus pneumoniae 548 by broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.
AID1233815Inhibition of Staphylococcus aureus DNA gyrase using relaxed pBR322 DNA as substrate after 3 hrs by DNA super-coiling assay2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.
AID67903Minimum inhibitory concentration against Enterococcus faecalis2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID591652Antimicrobial activity against Xanthomonas maltophilia IAC 739 after 18 hrs by agar dilution method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.
AID1187838Inhibition of Mycobacterium tuberculosis GyrA/GyrB using relaxed pBR322 as substrate at 0.97 uM after 30 mins by DNA supercoiling assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
AID205817Compound was tested in vitro for antibacterial activity against Staphylococcus aureus H199822000Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8
Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors.
AID207650Antibacterial activity against ofloxacin, oxacillin and erythromycin resistant Staphylococcus aureus strain 011GO761999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B.
AID717079Antibacterial activity against Escherichia coli MB28842012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID606876Inhibition of Hsp70 interaction with [35S]His-tagged HRI K199R mutant in reticulocyte lysate assessed as coadsorbed Hsp70 at 4 mM after 40 mins by SDS-PAGE and Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1187837Selectivity index, ratio of CC50 for mouse RAW264.7 cells to MIC for Mycobacterium tuberculosis H37Rv2014European journal of medicinal chemistry, Oct-06, Volume: 85Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
AID1580076Bactericidal activity against Escherichia coli ATCC 25299 at 50.4 uM in LB media after 24 hrs by time-kill assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID717083Antibacterial activity against Streptococcus pneumoniae CL2883 in presence of 2.5% lysed horse blood2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID363428Inhibition of Escherichia coli DNA gyrase2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
AID567628Inhibition of HSP90 in human MCF7 cells assessed as degradation of AKT protein after 48 hrs by Western blotting2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID1399852Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-Glo assay2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID396038Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP2 plasmid containing Enterobacter cloacae acrA gene by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID1193920Inhibition of Mycobacterium tuberculosis DNA GyrA/B heterotetramer assessed as inhibition of pBR322 supercoiling after 30 mins by gel electrophoresis2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
AID554400Antimicrobial activity against Pseudomonas aeruginosa isolate 2933 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1245290Inhibition of Staphylococcus aureus DNA gyrase assessed as inhibition of negative supercoiling of pBR322 DNA after 30 mins by agarose gel electrophoresis2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
AID717072Inhibition of Escherichia coli ATPase activity of DNA gyrase2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID603882Antiproliferative activity against human SKBR3 cells expressing HER2 after 72 hrs by MTS/PMS assay2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.
AID524393Antibacterial activity against Escherichia coli NKE1359 harboring deletion mutation in acrB protein and plasmid expressing BADnlpE gene in presence of increasing concentration of arabinose2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID717066Antibacterial activity against ciprofloxacin-resistant Staphylococcus aureus MB 5786 (R35)2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1303186Binding affinity to Escherichia coli DNA gyrase B2016European journal of medicinal chemistry, Jul-19, Volume: 117New N-phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATPase inhibitors of DNA gyrase.
AID1482552Inhibition of Haemophilus influenzae DNA topoisomerase 4 subunit ParC/ParE relaxation expressed in Escherichia coli BL21 (DE3) using supercoiled pBR322 DNA as substrate after 1 hr mins by agarose gel electrophoresis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.
AID1399851Antibacterial activity against Staphylococcus epidermidis ATCC 12228 by agar dilution method2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID524266Antibacterial activity against Escherichia coli NKE128 harboring deletion mutation in acrB and tolC protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID717081Antibacterial activity against Bacillus subtilis MB9642012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID279371Antibacterial activity against novobiocin-resistant Haemophilus influenzae ATCC 51907 with GyrB R140C mutation after 18 to 20 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID765362Cytotoxicity against ER-negative human SKBR3 cells expressing high level of HER2 after 3 days by MTT assay2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
AID530050Antimicrobial activity against Staphylococcus aureus 286607-R1 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
AID524263Antibacterial activity against Escherichia coli NKE127 harboring deletion mutation in acrB and cpxAR protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID392674Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in retinoic acid-differentiated human SH-SY5Y cells assessed as lactate dehydrogenase release at 10 nM2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line.
AID532763Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph mutant by broth dilution method in presence of chlorpromazine2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID446859Antibacterial activity against methicillin resistant Staphylococcus aureus 01A-1095 by NCCLS method2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV.
AID529159Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID479085Growth inhibition in Streptomyces 85E assessed as clear zone of inhibition at 20 ug/disk by hyphae formation inhibition assay2010Journal of natural products, May-28, Volume: 73, Issue:5
Coumabiocins A-F, aminocoumarins from an organic extract of Streptomyces sp. L-4-4.
AID524260Antibacterial activity against Escherichia coli NKE96 harboring deletion mutation in acrB protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID529511Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Biological activities of novel gyrase inhibitors of the aminocoumarin class.
AID251922Percent inhibition of filarial parasite Setaria cervi by compound at 5 ug/mL concentration; NI = no inhibition2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Syntheses of 2,4,6-trisubstituted pyrimidine derivatives as a new class of antifilarial topoisomerase II inhibitors.
AID1497260Antibacterial activity against Streptococcus pyogenes MTCC 4422018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Drug efficacy of novel 3-O-methoxy-4-halo disubstituted 5,7-dimethoxy chromans; evaluated via DNA gyrase inhibition, bacterial cell wall lesion and antibacterial prospective.
AID588984Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OAT32010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID369614Effect on ompF-lacZ fusion translation in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1415771Antibacterial activity against Escherichia coli JW5503 overexpressing gyrA/gyrB in absence of IPTG induction after 16 hrs by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID251762Percent inhibition of filarial parasite Setaria cervi by compound at 20 ug/mL concentration2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Syntheses of 2,4,6-trisubstituted pyrimidine derivatives as a new class of antifilarial topoisomerase II inhibitors.
AID311882Inhibition of Hsp90 in cell based assay2007Journal of natural products, Dec, Volume: 70, Issue:12
Derrubone, an inhibitor of the Hsp90 protein folding machinery.
AID1303172Inhibition of Staphylococcus aureus topoisomerase 4 assessed as supercoiling of relaxed pNO1 plasmid after 30 mins by SybrGOLD staining based fluorescence assay2016European journal of medicinal chemistry, Jul-19, Volume: 117New N-phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATPase inhibitors of DNA gyrase.
AID207789Compound was evaluated for its minimum inhibitory concentration against Staphylococcus aureus in presence of 10% serum2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
Fine Tuning of physico-chemical parameters to optimise a new series of novobiocin analogues.
AID1698681Inhibition of Escherichia coli topoisomerase IV by measuring relaxation activity incubated for 30 mins by fluorescence based assay2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
AID369075Antimicrobial activity against Staphylococcus aureus ATCC 6538 after 24 hrs by MTT assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Synthesis, structure and antibacterial activity of new 2-(1-(2-(substituted-phenyl)-5-methyloxazol-4-yl)-3-(2-substitued-phenyl)-4,5-dihydro-1H-pyrazol-5-yl)-7-substitued-1,2,3,4-tetrahydroisoquinoline derivatives.
AID557092Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 50% human serum2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1459321Inhibition of Staphylococcus aureus DNA gyrase B using relaxed pNO1 DNA as substrate incubated for 30 mins and measured by sybrGOLD staining based fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Linker-switch approach towards new ATP binding site inhibitors of DNA gyrase B.
AID1415745Antibacterial activity against novobiocin-resistant Escherichia coli CC7 harboring GyrB Arg136Ser mutant after 16 to 18 hrs in presence of PAbetaN by broth microdilution method2017MedChemComm, , Volume: 8, Issue:5
Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.
AID510747Antibacterial activity against Escherichia coli AG102MB harboring pSport1-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID1054857Inhibition of Mycobacterium tuberculosis DNA gyrase super coiling activity of relaxed pBR322 at 25 uM using ethidium bromide staining by agarose gel electrophoresis2013European journal of medicinal chemistry, , Volume: 70Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
AID1303184Inhibition of Escherichia coli topoisomerase 4 assessed as supercoiling of relaxed pBR322 plasmid after 45 mins by ethidium bromide staining based agarose gel electrophoresis2016European journal of medicinal chemistry, Jul-19, Volume: 117New N-phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATPase inhibitors of DNA gyrase.
AID206813In vitro antibacterial activity against Streptococcus pyogenes O2A1UC11999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B.
AID1157274Antibacterial activity against Escherichia coli 2884 by resazurin-based assay2014Journal of natural products, May-23, Volume: 77, Issue:5
Mahorones, highly brominated cyclopentenones from the red alga Asparagopsis taxiformis.
AID425957Antimicrobial activity against Staphylococcus aureus RN4220 harboring tetracycline-regulable expression vector pAJ96 expressing Staphylococcus aureus GyrB gene after 24 hrs by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Intrinsic novobiocin resistance in Staphylococcus saprophyticus.
AID554420Antimicrobial activity against mexXY operon inactivated Pseudomonas aeruginosa isolate 2729 obtained from cystic fibrosis patient by disk diffusion method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID571883Antibacterial activity against Escherichia coli KAM32 harboring plasmid pUC18 by CLSI broth microdilution method in presence of 25 ug/ml efflux pump inhibitor CCCP2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID717077Antifungal activity against Candida albicans MY10552012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
AID1266238Cytotoxicity against mouse RAW264.7 cells at 50 uM after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, Jan-01, Volume: 24, Issue:1
Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
AID206220In vitro antibacterial activity against Staphylococcus epidermidis 012GO39 OxaTei-R strain1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Synthesis and biological evaluation of coumarincarboxylic acids as inhibitors of gyrase B. L-rhamnose as an effective substitute for L-noviose.
AID206989Inhibitory activity against Staphylococcus aureus FDA 209P2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity.
AID279379Antibacterial activity against Staphylococcus aureus ATCC 29213 without plasmid2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID1266236Inhibition of Mycobacterium tuberculosis DNA gyrase assessed as inhibition of supercoiling activity using relaxed pBR322 plasmid as substrate after 30 mins2016Bioorganic & medicinal chemistry, Jan-01, Volume: 24, Issue:1
Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
AID425959Antimicrobial activity against Staphylococcus aureus RN4220 harboring tetracycline-regulable expression vector pAJ96 expressing Staphylococcus saprophyticus GyrB G85D mutant gene after 24 hrs by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Intrinsic novobiocin resistance in Staphylococcus saprophyticus.
AID303884Inhibition of basal ER-mediated transcription activity in MELN cells by measuring luciferase activity at 200 uM2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
AID206219In vitro antibacterial activity against Staphylococcus epidermidis 012GO39 OxaTei-R1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B.
AID554384Antimicrobial activity against Pseudomonas aeruginosa PAO1 by twofold macrodilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1558327Inhibition of NS2B-NS3 protease in Zika virus Puerto Rico/PRVABC5 infected in African green monkey Vero cells assessed as antiviral activity measured 48 hrs post infection by RT-PCR method2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1580096Antibacterial activity against wild type Acinetobacter baumannii ATCC 17978 by checkerboard assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID564970Downregulation of p27 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1335285Inhibition of Escherichia coli H560 DNA gyrase B ATPase activity after 30 mins by ammonium molybdate/malachite green-based phosphate detection assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
AID479095Growth inhibition in Streptomyces 85E assessed as bald phenotype around disk at 2.5 ug/disk by hyphae formation inhibition assay2010Journal of natural products, May-28, Volume: 73, Issue:5
Coumabiocins A-F, aminocoumarins from an organic extract of Streptomyces sp. L-4-4.
AID564975Antimicrobial activity against Mycobacterium bovis BCG by resazurine microtiter assay in presence of 0.1 mg/liter valinomycin2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1194333Inhibition of Mycobacterium tuberculosis GyrA/GyrB using relaxed pBR322 substrate incubated for 30 mins by ethidium bromide staining and electrophoresis based DNA supercoiling assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
AID1678526Inhibition of Staphylococcus aureus DNA gyrase using relaxed pNO1 plasmid DNA as substrate incubated for 30 mins by fluorescence assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Exploring the Chemical Space of Benzothiazole-Based DNA Gyrase B Inhibitors.
AID279376Antibacterial activity against Staphylococcus aureus ATCC 29213 carrying plasmid expressing GyrB T173N mutant2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
AID524265Antibacterial activity against Escherichia coli NKE159 harboring deletion mutation in acrB, cpxAR protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID369073Antimicrobial activity against Escherichia coli ATCC 35218 after 24 hrs by MTT assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Synthesis, structure and antibacterial activity of new 2-(1-(2-(substituted-phenyl)-5-methyloxazol-4-yl)-3-(2-substitued-phenyl)-4,5-dihydro-1H-pyrazol-5-yl)-7-substitued-1,2,3,4-tetrahydroisoquinoline derivatives.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1811Experimentally measured binding affinity data derived from PDB1997Biochemistry, Aug-12, Volume: 36, Issue:32
The entropic penalty of ordered water accounts for weaker binding of the antibiotic novobiocin to a resistant mutant of DNA gyrase: a thermodynamic and crystallographic study.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1997Biochemistry, Aug-12, Volume: 36, Issue:32
The entropic penalty of ordered water accounts for weaker binding of the antibiotic novobiocin to a resistant mutant of DNA gyrase: a thermodynamic and crystallographic study.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2014ACS chemical biology, Sep-19, Volume: 9, Issue:9
Structures of kibdelomycin bound to Staphylococcus aureus GyrB and ParE showed a novel U-shaped binding mode.
AID1799875Enzyme Assay from Article 10.1074/jbc.M112.419069: \\The naphthoquinone diospyrin is an inhibitor of DNA gyrase with a novel mechanism of action.\\2013The Journal of biological chemistry, Feb-15, Volume: 288, Issue:7
The naphthoquinone diospyrin is an inhibitor of DNA gyrase with a novel mechanism of action.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,155)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901200 (55.68)18.7374
1990's299 (13.87)18.2507
2000's307 (14.25)29.6817
2010's282 (13.09)24.3611
2020's67 (3.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.13 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index95.78 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (0.66%)5.53%
Trials0 (0.00%)5.53%
Reviews84 (3.70%)6.00%
Reviews0 (0.00%)6.00%
Case Studies3 (0.13%)4.05%
Case Studies0 (0.00%)4.05%
Observational1 (0.04%)0.25%
Observational0 (0.00%)0.25%
Other2,168 (95.46%)84.16%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
A Phase 1 Study of the Polymerase Theta (POLQ) Inhibitor Novobiocin in BRCA-Mutant and Other DNA Damage Repair-Deficient Solid Tumors [NCT05687110]Phase 130 participants (Anticipated)Interventional2023-07-06Suspended(stopped due to Other - FDA Clinical Hold)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]